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 Postnatal muscle growth is dependent on myonuclear accretion and subsequent 
protein synthesis and accumulation.  Altering the ability of muscle resident stem cells 
(satellite cells, SC), which provide nuclei to the growing muscle fiber, to progress through 
their myogenic lineage can have lifelong effects on muscle growth and repair.  The use of 
butyrate, a histone deacetylase (HDAC) inhibitor, has promoted SC myogenesis in vitro.  
In animal models, dietary butyrate has improved growth performance and has had 
promising results in treating myopathic conditions, but the impact of dietary butyrate on 
SC activity and the direct promotion of muscle growth have not been examined.  In the 
first experiment, we investigated whether the use of a physiologically relevant 
concentration of butyrate (0, 0.1, 0.5, or 1mM) could enhance the myogenic potential of 
porcine SC.  We found increased expression of myogenin, the late stage myogenic 
regulatory factor, and increased SC fusion in the treated groups, suggesting an increased 
capacity during terminal differentiation.  We further tested this hypothesis by conducting 
an animal study to test the effects of tributyrin, a butyrate pro-drug, on in vivo SC behavior.  
We found that tributyrin inclusion (0.25% and 0.5%) into the milk replacer of neonatal 
  
piglets led to significant increases in muscle DNA content, suggesting increased 
myonuclear accumulation.  The neonatal portion (21-days) of the study was repeated, and 
the animals were then weaned and crossed into dry nursery treatment diets.  At the end of 
the 37-day nursery feeding, animals that received tributyrin in their milk replacer formula 
weighed significantly more and had increased muscle hypertrophy than the untreated 
animals.  Also, SC from treated animals responded similarly ex vivo to those in the first 
experiment, suggesting an increased capacity to progress through the differentiation 
process.  We determined in our final experiment that tributyrin supplementation altered the 
epigenetic landscape of SC by globally reducing the transcriptionally repressive chromatin 
mark H3K27me3 around key genes.  In addition, we found that this is not the sole 
mechanism through which butyrate alters SC behavior.  These findings help support the 
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Chapter 1: Literature Review 
 
Introduction 
The ability for animals to grow and accumulate muscle mass postnatally relies on a distinct 
stem cell population residing within the muscle and along the myofibers (17, 74, 75, 87).  
These stem cells, referred to as satellite cells due to their juxtaposition beneath the 
basement membrane and outside the sarcolemma of the myofibers (64), are activated and 
will proliferate, differentiate and fuse into the growing myofiber.  This contribution of 
nuclei to the myonuclear domain can then aid in protein synthesis, accretion, and 
subsequent muscle hypertrophy (3).  It is during the earliest stages of post-natal 
development that satellite cells are most active and provide the majority of nuclei found in 
the adult muscle fiber (17, 46, 102).  Altering the ability of satellite cells to progress 
through their myogenic lineage can alter lifetime muscle growth and regeneration (1, 32, 
47, 50, 68, 72, 91, 92, 98) which makes them a practical target when trying to enhance 
muscle hypertrophy.  Recently the use of histone deacetylase (HDAC) inhibitors have been 
shown to be effective at altering muscular homeorhetic characteristics in muscle disease 
models (27, 37, 71) and exhibited positive effects when supplied to satellite cells in vitro 
(49, 50).  Once such HDAC inhibitor, butyrate, has led to improved growth performance 
measurements when included in the diet of agricultural species (8, 57, 58, 60, 85).  Despite 
what seems to be promising outcomes, research into satellite cell programming effects in 
response to butyrate treatment in these models have not been evaluated.  Tributyrin, a 
butyrate pro-drug, provides an efficient means to deliver increased amounts of butyrate 





be that butyrate may act on the epigenetic landscape of satellite cells, whereby 
supplementation through dietary tributyrin may enhance muscle growth through altered 
satellite cell programming.  This chapter summarizes the relevant literature on the effects 
of butyrate and tributyrin on satellite cell behavior and their applicability as a feed additive, 
in addition to pertinent satellite cell physiology with regards to muscle growth, myogenic 
commitment, and epigenetics.     
   
Satellite cell physiology and muscle growth 
Satellite cells are a heterogeneous population of stem cells required for post-natal muscle 
growth and repair and arise embryonically from somites that make up the dermomyotome 
(11).  These embryonic myogenic precursor cells eventually will go into a state of 
quiescence wedged between the basement membrane and the plasmalemma of the muscle 
fibers (Figure 1-1) (7).  It is this pool of undifferentiated satellite cells that are required for 
post-natal muscle growth and repair (47, 98) which is orchestrated through a series of 
tightly controlled regulatory mechanisms.  These processes govern the rate of muscle 
hypertrophy in the growing animal and ultimately have an impact on their lifetime lean 
growth potential (109) and muscle regenerative capacity (93) .  Changes in the myogenic 
potential and the cascade of events that detail satellite cell myogenesis have revealed 
avenues for possible manipulation to enhance growth, improve health, and prevent 









Figure 1-1.  Illustration of the anatomical location of skeletal muscle resident stem cells (satellite cells).  
Skeletal muscles are separated into bundles of multinucleated fibers.  Satellite cells reside along these muscle 
fibers, outside the plasmalemma and underneath the basal lamina (adapted from Dumont et al., 2015). 
 
Fetal myogenesis involves the establishment of primary and secondary myofibers, marked 
by expansive hyperplasia from the fusion of myogenic precursor cells (MPCs) (22, 83).  
Pax3-positive (paired box domain-3), and to some extent Pax7-positive, cells represent a 
pool of MPCs that form primary myofibers and make up a scaffold with which secondary 
myofibers will align (44).  These MPCs will generally have a second wave of migration, 
differentiation, and fusion to form secondary myofibers surrounding the primary myofibers 
(92).  A subpopulation of MPCs will exit the cell cycle and occupy the satellite cell niche 
between the basement membrane and sarcolemma (80).  The process through which MPCs 
and ultimately satellite cells progress through their myogenic lineage is under the control 
of a series of hierarchal transcription factors (9).  MPCs are denoted by the expression of 
Pax3 (4, 12), but not necessarily the expression of Pax7; this contrasts with satellite cells 
in which Pax7 is an absolute requirement for post-natal myogenesis (81, 98).  Both MPCs 





timely expression of muscle regulatory factors (MRFs).  Common to both cell types are 
the primary MRF MyoD and the secondary MRF myogenin which are required for terminal 
differentiation (47, 68, 105).  There is some built in redundancy in the MyoD family of 
MRFs; however, for this review I will focus the discussion mainly on MyoD and myogenin 
and their role in post-natal muscle growth (Figure 1-2) (for a detailed review, see 
Bentzinger et al. 2012 (9)).   
 
Figure 2-2.  Illustration of transcription factors regulating satellite cell lineage progression.  Muscle precursor 
cells (MPC) involved in fetal myogenesis skip straight to myoblasts.  Some MPCs will go into a state of 
queisence, marked by upregulating Pax7.  Once activated, satellite cells will commit to a myogenic lineage 
and express MyoD.  At the onet of differentiation, myoblast downregulate Pax7 and express myogenin 






Apart from their physical location, satellite cells can be identified by their expression of 
the Pax7, which has been described as a master regulator of satellite cell specification (15, 
56).  Satellite cells possess the ability to activate, proliferate, and give rise to either 
committed myogenic daughter cells or self-renew and eventually return to a mitotically 
quiescent state.  Pax7 plays an important role in the process of lineage fate determination 
and is upregulated upon activation, specifying myogenic commitment by inducing the 
expression of Myf5 (66).  Those cells expressing Myf5 represent a satellite cell committed 
to myogenesis that will ultimately start expressing MyoD.  Myf5-negative satellite stem 
cells have the unique ability to asymmetrically divide by producing My5-positive daughter 
cells (54).  Once satellite cells start to express MyoD they are generally referred to as 
myoblasts and it is at this stage where differential expression patterns of Pax7 and MyoD 
will control the fate between proliferation and determination (79).  Where a high 
Pax7:MyoD expression pattern favors continued proliferation and inhibition of 
differentiation (78), and a low Pax7:MyoD promotes the differentiation of myoblasts to 
myocytes.  Myocytes are marked by the upregulated expression of myogenin, facilitated 
by MyoD, and rapidly differentiate (84).  Other molecular cues also aid in the myogenic 
differentiation program by inhibiting Pax7 expression (23, 33).  Myogenin and Pax7 
expression are mutually exclusive and this cross-inhibitory interaction plays a key role in 
cell fate determination (79, 94).  Once myogenin expression begins, myocytes will 
terminally differentiate and fuse together to form myotubes, characterized by the 
expression of the contractile protein myosin heavy chain (70).  Myogenin upregulation 
directly activates myotube associated genes and is required for the expression of most of 





factors regulate satellite cell fate determination and are hallmarks of their progression 
through their myogenic lineage.  Changes in satellite cell dynamics marked by these 
transcription factors have shown to have a dramatic effect on post-natal muscle growth and 
development. 
 
Altering the myogenic potential of satellite cells has shown to have profound effects on the 
lifetime muscle growth potential and regeneration (1, 72, 93).  Post-natal muscle growth is 
considered a hypertrophic event (increase in muscle fiber size), as the increase in muscle 
fiber number (hyperplasia) has usually ceased right around the time of birth for most 
animals (103).  In neonatal animals, the ratio of mononuclear satellite cells to 
multinucleated myotubes is the largest and this ratio steadily declines as an animal ages 
(2).  It is also during this period that muscle growth is this most rapid, marked by enhanced 
myonuclear proliferation and the muscle protein accumulation (97).  As the animal ages, 
the factional rate of protein synthesis steadily declines (31).  Similar pathways that 
stimulate satellite cell myogenesis also activate protein translation machinery in parallel 
during neonatal growth.  Nutrition has shown to be a dominant controlling factor with 
regards to altering both satellite myogenesis and protein synthesis pathways.  After the 
ingestion of a meal, protein synthesis is promoted by altering mammalian target of 
rapamycin (mTOR) signaling which acts to phosphorylate eIF (eukaryotic initiation 
factor), 4E binding protein 1 (4EBP1), and the ribosomal protein S6K1 (31).  Restriction 
in total food and protein intake (99), dietary mineral and vitamin restriction (1, 35), and 
certain amino acid deficiencies (32, 110) during the neonatal period severely impact the 





subsequent fusion into myofibers.  Activators of protein translation such as exercise and 
muscle damage have also shown to be a potent stimulator of satellite cell activation (10, 
39), and conversely, disuse and aging leads to muscle atrophy and impaired satellite cell 
function (13, 93).  These known stimuli have aided in the discovery of regulatory networks 
that provide targets to be manipulated for enhanced muscle hypertrophy. 
 
There has been a great deal of research into the regulatory pathways involved around the 
epigenetics of satellite cell fate.  Epigenetic regulators have been identified as being 
involved in the chromatin remodeling around Pax7 and the MRFs, ultimately dictating their 
expression patterns (73, 100).  Satellite cells, as most stem cells do, remained “poised” to 
start the myogenic program once activated (28).  The epigenetic marks associated with 
satellite cells take one of two broad profiles, one which favors proliferation or one which 
favors differentiation.  Once activated, satellite cells begin to proliferate while repressing 
those genes associated with the differentiation part of the myogenic program (34).  In 
general, this is accomplished by silencing muscle genes through the deposition of methyl 
groups on lysine 27 of the histone 3 (H3K27me3) (5) by the methyltransferase enzyme, 
enhancer of zeste-2 (EZH2), a subunit of the polycomb repressive complex-2 (PRC2) (21).  
The EZH2 subunit plays a critical role in preventing differentiation by associating with the 
myogenin promoter (5), along with other genes associated with non-muscle lineage fates 
(108).  Concomitant with the silencing of differentiation genes, is the permissive chromatin 
mark, H3K4me3 which aids in Pax7, MyoD, and cell cycle gene expression (66).  Upon 
induction to differentiate, PRC2-EZH2 leaves the regulatory region of myogenin and 





and “switching-off” proliferation (82).  The H3K27me3 mark around muscle specific genes 
is then removed by a demethylase that has been recruited to their promoters (34).  
Corresponding with demethylase activity is the down regulation of histone deactylase-1 
(HDAC1) (62) and an increase in acetylation of histone tails by histone acetyltransferases 
(HATs) (67) to allow for chromatin relaxation and access to muscle differentiation target 
genes.  A complex formed by the association of HDAC1 and MyoD is also interrupted 
which allows for acetylated MyoD to target and upregulate myogenin (20, 90).  Taken 
together, these “switches” allow for the timely regulation of satellite cells to differentiate 
into proliferating myoblasts, form myocytes, and quickly fuse into myotubes. 
 
HDACs play a key role in the switching on of the differentiation program and switching 
off cycle/proliferation mechanisms.  HDACs target the DNA and compact chromatin 
structure, repressing transcription directly.  They target specific regions of DNA by 
associating with other regulatory proteins and are integral in the transition of proliferative 
to the differentiative nuclear state in satellite cells (67).  The significance of the role that 
HDACs play in satellite cell physiology has become more defined recently and offers a 
potential mechanism that may be exploited for enhanced muscle growth. 
 
Butyrate and histone deacetylase inhibitors 
Research has been accumulating over the past several years about the use of HDAC 
inhibitors in treating muscle myopathies (73, 100).  Butyrate, a 4-carbon short chain fatty 
acid, is a known inhibitor of HDACs (19, 63) that has also recently proved efficacious at 





differentiation in satellite cell cultures (49, 50).  Dietary butyrate has proved beneficial for 
intestinal health statuses and has been used in the animal agriculture industry since the late 
1980’s (41).  Despite the mounting evidence indicating its beneficial effect on muscle 
homeorhesis and the development of new butyrate glycerides, research has yet to determine 
the influence of dietary butyrate on muscle growth.  
 
In 2002, Iezzi and colleagues (49) were the first to report the possible benefits of HDAC 
inhibitors on satellite cell myogenesis.  The researchers noted increases in myoblast fusion 
and enhanced terminal differentiation when the HDAC inhibitors were added to satellite 
cell cultures.  HDAC inhibitors were originally researched for their ability to arrest growth 
and force differentiation or apoptosis in cancer cells (30, 63).  It has now been found that 
inhibition of class I HDACs primarily, confers beneficial effects on satellite cell 
myogenesis through the disruption of the MyoD-HDAC1 complex, allowing the 
expression of late stage muscle specific genes (62, 67, 90).  There is also some evidence 
that inhibiting class II HDACs aids in the activation of MEF2 whose activity is otherwise 
blocked by hypoacetylation (61, 90).  Treatment of embryonic stem cells with HDAC 
inhibitors also revealed that not only are HDACs directly inhibited leading to an increase 
in histone acetylation, but there is also an indirect effect on the epigenetic programming 
marks associated with histone methylation (52).  These results indicate that HDAC 
inhibitors selectively enhance those genes associated with normal activation during the 
differentiation process. With the understanding that many of these factors controlling 
satellite cell fate may be targeted and manipulated, the use of HDAC inhibitors for the 





sclerosis (ALS) (95, 112), and sarcopenia or atrophy (106) has had positive results.  Minetti 
et al. (30) found that MDX mice treated with TSA showed a recovery in exercise 
performance and an almost 2-fold increase in fiber cross sectional area.  When TSA was 
used to treat a mouse model of ALS, Yoo et al. (112) showed decreased muscle atrophy by 
exerting a neuroprotective effect, as well as inhibiting HDACs known to promote muscle 
atrophy.  Walsh et al. (107) found similar results in butyrate-fed mice, indicating that 
butyrate may help in the preservation of muscle mass during aging.  The outcomes of these 
studies have warranted a more comprehensive look at the potential role and benefit that 
HDAC inhibitors play in enhancing muscle growth.    
 
Butyrate is an HDAC inhibitors that has been well researched, but has not been fully 
evaluated as a muscle growth promoter.  Butyrate is the natural byproduct of microbial 
fermentation of fiber in hind gut (14) and has been utilized for the treatment of human 
neoplasms (88).  It’s use on satellite/myogenic cell cultures has been mostly documented 
as having detrimental effects to the normal myogenic progression (40, 51, 59); however, 
the study by Iezzi et al. (49) characterized the potential benefit of the butyrate on satellite 
cell myogenesis.  Iezzi and colleagues note that exposure proliferating myoblast to butyrate 
enhanced the formation of multinucleated myotubes during differentiation after it was 
removed.  These results are in agreeance with the notion that HDAC inhibitors are selective 
in the genes that are targeted and correlate with proliferating stem cells (26) (Figure 1-3).  
It is for this reason that the mechanism behind butyrate’s action make it a potential modifier 
of satellite cell fate.  Butyrate’s use as a pharmacologic for in vivo myopathic conditions 





the effect that butyrate has on in vivo satellite cell behavior has not be described.  As is the 
case with other HDAC inhibitors, they are currently being researched for the treatment of 
DMD and another myopathies (27).  Although these studies have highlighted the potential 
benefit to muscle tissue, they have been sparse in describing the potential benefit to 
promoting muscle growth and regeneration.  Likewise, butyrate has been well researched 
as a feed additive to promote intestinal health (18, 45), but its effect on muscle growth 
specifically has not been evaluated.  Studies dating back to the 1950’s have attributed the 
positive impacts of butyrate on animal growth to some component of intestinal importance.  
This led to investigations into the benefits of butyrate’s modulation of transformed cell 
lines (6, 48), as well as in vivo models of colonic malignancies as fiber in the diet can 
expose the lower gastrointestinal tract to butyrate and its HDAC inhibitory properties (14, 
65).  Collectively, these studies indicate that butyrate may have a positive impact on muscle 













Figure 3-3.  Illustration of the epigenetic status of satellite cells in response to HDAC inhibitors.  Genes that 
are susceptible to HDAC inhibition mirror those that are activated during differentiation (adapted from 
Consalvi et al., 2011). 
 
The results of satellite cell culture studies are unclear and contradictory (40, 49-51, 59), 
but they allude to an enhanced or forced differentiation of satellite cells.  Part of the 
confusing results may lie with the high concentration (3-7mM) and/or timing of butyrate 
applied to the cultures.  One study involving human patients revealed physiologically 
relevant concentrations peaked at 59µM when administered sodium butyrate at 
500mg/kg/day by continuous intravenous infusion (69).  Given an intravenous dose 
(1.25g/kg), rodents also showed a similar clearance rate, and after 30m, plasma butyrate 
concentrations fell below 1mM (38).  Dietary, or enteral, administered sodium butyrate 
with mice had similar results, with concentrations falling below 1mM after 90m.  While 
the half-life of circulating butyrate is around 5m (69, 86), exposing satellite cells to 





more than just the myogenic program.  It has been shown that butyrate is extremely 
effective at arresting cell growth and proliferation in culture (88, 89).  Therefore, applying 
high concentrations of butyrate for long periods of time to sub-confluent satellite cells 
during the proliferative stage would blunt myogenesis as the forced differentiation of sub-
confluent satellite cells has been shown to reduce proper myotube formation (104).  There 
has been research into butyrate pro-drugs with superior pharmacokinetics that allow for 
enhanced delivery of butyrate to systemic tissues for sustained periods (24, 25, 38, 43).  
Utilizing these butyrate pro-drugs could provide an effective means at exposing satellite 
cells to physiologically relevant concentrations (≤1mM) of butyrate in vivo.  
 
One key property of exposing satellite cells to butyrate in vivo relies on continuous 
supplementation throughout periods of muscle growth.  While intravenous delivery of 
butyrate and synthetic butyrate carriers may be effective at treating malignant cell 
populations (86), oral delivery through food remains the only practical way to enhance 
post-natal muscle growth for extended periods of time.  To this end, the butyrate pro-drug 
tributyrin may be the most appropriate alternative to promote muscle growth through 
dietary inclusion.  
 
Tributyrin, a butyrate pro-drug 
The beneficial effects of butyrate in treating myopathic models has been demonstrated, but 
its use as a muscle growth promoter has not been investigated.  Utilizing tributyrin to 
achieve sustained systemic concentrations of butyrate may impact muscle growth and 





effect on muscle tissue (16), most of what is known about the effectiveness of tributyrin 
and butyrate on peripheral tissues has been from studies involving cancer or 
gastrointestinal diseases (24, 36, 55).  These studies have however, demonstrated that oral 
tributyrin provides far superior pharmacokinetics over butyrate at reaching systemic tissues 
as well as the ease of handling without the obnoxious odor that butyrate presents (18).  Just 
as butyrate has been investigated for the potential intestinal health benefits in the animal 
agriculture industry, so has tributyrin, with some studies indicating increased growth rate.  
Together, these results support the notion that oral tributyrin would expose muscle tissue 
to sufficient concentrations of butyrate needed to enhance myogenesis.  With regards to 
outcomes involving the promotion of muscle growth, questions about delivery, inclusion 
rates, and effectiveness still remain.  
 
Butyrate has been widely used in the animal industry to protect the gut health of animals 
and improve the trophic status of the intestine (41, 96).  To this end, studies involving oral 
tributyrin have proved to be a more effective means of delivering butyrate to the entire 
digestive tract aimed at improving growth and/or performance (Table 1-1); the results of 
which have demonstrated that butyrate and/or tributyrin may influence overall growth as 
evident by increased final body weights and average daily body weight gain.  Apart from 
an apparent increase in these growth measures seen in the animals receiving treatment 
diets, is the decrease in adiposity linked to an increased fatty acid oxidation and 
thermogenesis; suggesting muscle hypertrophy is the cause for increased weight gain (8, 
42, 107, 111).  Most, if not all, of the animal growth and performance models have been 





models, growing animals can give us an insight into possible actions exerted on satellite 
cell behavior.  The potential for lifetime muscle growth has been linked to when satellite 
cells are most active and when rapid myonuclear accretion occurs (31, 76), and that 
hypertrophy cannot occur without satellite cell mediated myonuclear accretion (53, 77).  
Consequently, it would appear that oral supplementation of butyrate may in fact be 
promoting muscle growth by altering satellite cell programming through HDAC inhibition 








Table 1-1: Summary of relevant effects of butyrate and tributyrin on animal growth and performance 
 
*- Feed efficiency or feed conversion ratio, Feed:Gain 
a- Mixture of tributyrin and lactitol  
b- On a dry matter basis 
c- Mixture of 30% mono-, 50% di, and 20% tributyrin 
d- Encapsulated or coated sodium butyrate 
e- Mixed 0.3% 1-monobutyrate and 0.3% butyrate glyceridesb 
f- Butyrate glycerides: two studies using monobutyrin and mono- and tributyrin  
g- Sows fed treatment diet at 77d of gestation through farrowing to end of lactation, or sodium butyrate was supplied just during lactation to neonatal piglets 
  Results   
Feed Additive/Inclusion Rate Animal Model Effect on Growth Effect on Performance* Mechanism of Action Reference 
Sodium Butyrate/0.17% Piglet (Weaned)   Improved intestinal health and development Galfi and Bokori (1990) 
Sodium Butyrate/0.08% Piglet (Weaned) Improved intestinal development Piva et al. (2002) 
Tributyrina/1.0% Piglet (Weaned) Improved intestinal health and development Piva et al. (2002) 
Sodium Butyrate/0.3%b Piglet (Neonatal) ---- Improved intestinal efficiency and development Kotunia et al. (2004) 
Butyrate Glyceridesc/0.1-4% Chicken 	 	 Improved intestinal development Leeson et al. (2005) 
Sodium Butyrate/0.3% Piglet (Weaned) ---- Improved intestinal health dynamics Manzanilla et al. (2006) 
Sodium Butyrate/0.1-4% Piglet (Weaned) 	 	 No appreciable improvements Biagi et al. (2007) 
Tributyrina/0.3% Piglet (Weaned) Improved intestinal development Piva et al. (2008) 
Sodium Butyrate/0.3% Calf Improved intestinal efficiency Guilloteau et al. (2009) 
Sodium Butyrate/0.3% b Piglet (Neonatal & Weaned) 	 Improved intestinal efficiency Le Gall et al. (2009) 
Sodium Butyrate/0.35% Calf (Neonatal & Weaned) 	 Improved intestinal development Katoh et al. (2011) 
Butyrate/0.3% Piglet (Perinatal)g ---- Improved lipid metabolism Lu et al. (2012) 
Sodium Butyrate Fish Improved intestinal efficiency Robles et al. (2013) 
Sodium Butyrated/0.15% Piglet (Weaned) Improved intestinal health dynamics Chiofalo et al. (2014) 
Sodium Butyrated/0.1% Piglet (Weaned) Improved Intestinal permeability and microbiome Huang et al. (2015) 
Tributyrin/0.05% Piglet (Neonatal) 	 Improved intestinal development Dong et al. (2016) 
Coated Calcium Butyrate/0.02-4% Chicken Improved intestinal efficiency Kaczmarek et al. (2016) 
Sodium Butyrate/1g/day Piglet (Neonatal) 	 	 Altered Microbiome Xu et al. (2016) 
Butyrate Glyceridese/0.6% Chicken Improved lipid metabolism Yin et al. (2016) 





The butyrate triacylglyceride, tributyrin, is used in many foods as a flavoring agent and 
adjuvant and is currently approved as a dietary additive (4).  Tributyrin was originally 
synthesized as an oral prodrug aimed at combating neoplastic growths by sustaining 
systemic levels of butyrate (5, 7, 9, 13).  Lipases in the small intestine may cleave off two 
of the butyric acid moieties, but leave behind the 2-monobutyrin for absorption into the 
enterocyte (17).  The attached butyric acid molecule reaches circulation rather than be 
immediately utilized for energy by the enterocyte (25).  There is also evidence that intact 
tributyrin can be absorbed and make it into systemic circulation (26), which would allow 
for gradual hydrolysis of the triglyceride and sustained concentrations s of butyrate in 
circulation.  Tributyrin is also well tolerated when given orally  (4, 21) and does not have 
the caustic odor or corrosiveness associated with butyric acid or its salts (primarily sodium 
or calcium butyrate) that limits their use when included in the diet (19).  So, with the aim 
of targeting muscle tissue, dietary inclusion of tributyrin may not only provide intestinal 
health benefits but is also more suitable for providing butyrate systemically to alter satellite 
cell myogenesis. 
 
From a practical stand point, there are several questions that need to be addressed when 
including tributyrin into the diet for promoting muscle growth.  Since tributyrin inclusion 
increases systemic circulation of butyrate, other proliferating cell populations may be 
affected.  There is some evidence that the mesenchymal stem cell (MSC) population, 
another tissue resident stem cell population linked to lifetime bone and adipose (as well as 
other) tissue growth, may adopt an osteogenic lineage when exposed to butyrate (3).  





adiposity.  Another question that remains is the rate of inclusion of tributyrin into the diet.  
It has been noted that at certain amounts of butyrate or tributyrin, feed intake declines (15) 
which has been linked to certain states of mild ketosis caused by intake of exogenous 
ketone bodies (22).  Overall, this could limit the supply of available nutrients needed for 
muscle hypertrophy, masking the effects of tributyrin supplementation.  From this 
standpoint, inclusion rates of tributyrin necessary to have a positive effect on muscle 
growth without experiencing a decline in feed intake would need to be determined.  Some 
authors have also looked at and suggested that the timing (pre- or post-weaning) of 
butyrate/tributyrin inclusion in the diet may have certain periods of effectiveness with 
regards to growth (1, 14, 20).  It may be that continual supplementation of tributyrin into 
the diet may not necessarily be needed to achieve positive effects on muscle growth and 
lifetime lean tissue accretion.    
  
Conclusion 
Altering the ability of satellite cells to progress through their myogenic lineage is key to 
enhancing the post-natal growth of muscle and lifelong potential for lean tissue accretion.  
As evidenced by the positive outcomes seen when animals are given a diet supplemented 
with butyrate or tributyrin, early-life intervention with a potential hypertrophic stimulus 
could have lifelong impacts on muscle growth and regeneration (24).  Butyrate and other 
compounds have shown to positively influence satellite cell myogenesis when treated in 
culture (10, 11); although, the concentration and timing of butyrate application may not 
have been physiologically relevant.  These changes; however, have been linked to their 





cells (6, 18).  The beneficial effects on muscle tissue seen in some animal disease models 
treated with butyrate (2, 8, 23, 27, 28) highlight the potential for therapeutics by inhibiting 
HDACs.  The potential for oral butyrate to affect muscle growth has been presented in a 
variety of animal models (Table 1-1), but these studies were aimed at improving growth 
through improved intestinal dynamics and did not investigate the impact of butyrate on 
satellite cells or their contribution to the observed measures of growth.  It is thought that 
through changes in the epigenetic landscape, butyrate treatment may epigenetically modify 
the myogenic potential of tissue resident stem cells (12, 16).  The butyrate prodrug 
tributyrin is a better alternative to dietary butyrate inclusion due to its pharmacokinetics 
(9) and ease of use (4).  It is my hypothesis that when included into the diet, tributyrin may 
promote muscle growth by altering satellite cell myogenesis.  It is important to determine 
what effect butyrate has on satellite cells at physiologically relevant concentrations and 
during all periods of the myogenic lineage.  Also, it appears that butyrate treatment may 
have a more profound effect on growth when supplemented earlier in life (14, 20) which 
would be indicative of when satellite cells are most active.  Ascertaining the effects of 
tributyrin supplementation during the early stages of life is central to understanding the 
degree to which tributyrin may be able to promote muscle growth.  The outcomes generated 
by investigating these issues may lead to a more efficient and sustainable means of lean 
meat in the production industry and also have an impact on the potential treatment of 
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Chapter 2: The HDAC inhibitor sodium butyrate promotes late stage 




The ability of satellite cells, (muscle specific stem cells) to proliferate and differentiate 
through their myogenic lineage is critical for muscle growth, regeneration and 
repair.  Understanding the underlying mechanisms responsible for satellite cell myogenesis 
will improve our understanding of muscle growth and may provide targets for therapeutics 
for musculoskeletal diseases.  Muscle injury models treated with histone deacetylase 
(HDAC) inhibitors have had positive results on muscle growth, but the underlying 
mechanisms have not been elucidated.  Previous studies have reported pleotropic effects 
of the HDAC inhibitor, butyrate, on the progression of satellite cells through their 
myogenic program.  We investigated whether the use of a physiologically relevant 
concentration of butyrate could enhance the myogenic potential of porcine satellite 
cells.  Satellite cells isolated from neonatal piglets were treated with sodium butyrate (0, 
0.1, 0.5, or 1mM) and myogenic potential was analyzed during proliferation and 
differentiation.  Proliferation was reduced in a dose-dependent manner with increasing 
sodium butyrate concentrations.  The relative expression of Pax7 significantly decreased 
during proliferation, while the late stage myogenic regulatory factor, myogenin, increased 
in the sodium butyrate treated groups.  Satellite cells fused and formed myotubes more 
rapidly with increasing sodium butyrate concentrations.  These findings suggest that 
butyrate may serve as a muscle growth promoter and increase regenerative capacity of 






Satellite cells are a heterogeneous population of muscle progenitor and stem cells, which 
are responsible for post-natal muscle development and self-renewal (14).  Satellite cells 
reside along the muscle fiber outside the sarcolemma under the basal lamina and provide 
myonuclei to the growing muscle fiber (39).  Enhancing the ability of satellite cells to 
progress through their myogenic lineage can have profound effects on an animal’s lifetime 
muscle growth and regeneration (1, 8).  As with other tissues, the neonatal period represents 
a crucial time for muscle development and growth through enhanced satellite cell 
proliferation (2, 10) and rapid myonuclear accumulation (18, 50).  The process through 
which satellite cells proliferate and fuse to become myofibers is tightly regulated by the 
timely expression of transcription factors and signaling molecules (6); these key factors 
provide potential targets for epigenetic modification to enhance myogenesis (38, 54).  
Butyrate, a short chain fatty acid, is known to alter epigenetic regulators in stem cells (11, 
45, 46), but its effectiveness at promoting myogenesis of satellite cells remains unclear. 
 
Satellite cells, first described by Mauro (1961) were identified as a population of 
mononuclear cells responsible for the skeletal muscle regeneration.  Since being first 
described, it is now known that this population of muscle resident cells are indeed stem 
cells, capable of self-renewal and providing muscle progenitors (14).  Postnatally, muscle 
growth is considered a hypertrophic event and satellite cells contribute new nuclei to these 
growing muscle fibers (48).  Subsequent protein synthesis is incumbent on myonuclear 
accretion, which can limit the fractional rate of muscle growth and repair (40, 50).  The 





growing myofibers is under the control of a hierarchal transcriptional network (6).  Satellite 
cells are marked by their universal expression of the paired-homeobox transcription factor 
Pax7 (43), a key transcription factor that is required for satellite cell specification (31, 49, 
52) and the prevention of terminal differentiation (42).  Pax7 aids in the regulating the 
expression of a network of downstream myogenic regulatory factors (MRFs), namely 
MyoD and myogenin (60). The interaction of the expression patterns of Pax7 and MyoD 
have been determined to have an impact on satellite cell commitment fate, where an 
upregulation of Pax7 will prevent differentiation (44).  A reduction in MyoD expression 
results in a state resembling satellite cell quiescence or self-renewal (36) while the 
upregulation of MyoD marks the beginning of differentiation and myoblast commitment 
(4).  Downstream and a target of MyoD, is the MRF myogenin, whose expression marks 
terminal differentiation into myocytes (51).  Loss of myogenin results in pools of 
undifferentiated mononuclear cells and the inability to complete late stage myogenesis by 
forming multinucleated muscle fibers (25, 56).  Myogenin works synergistically with 
MyoD at common set of muscle genes (12) and alone in the promotion of muscle specific 
gene transcription (7, 16).  This network of transcription factors that make up the myogenic 
program of satellite cells and the epigenetic mechanisms that regulate their expression have 
been offered as potential targets for improving muscle growth and disease outcomes (38, 
53, 54). 
 
Of particular interest are epigenetic modifiers that inhibit HDACs as they have shown to 
be beneficial in treating some myopathy models (9, 21, 37, 57, 58).  Butyrate has also had 





to an improved intestinal immune response and lipid metabolism (26, 59).  The HDAC 
inhibitory properties of butyrate were initially described as a way to treat human 
malignancies of the colon (33).  Butyrate is a 4-carbon fatty acid that is the byproduct of 
fiber fermentation in the gut (45) and inhibits the activity of class I and II HDACs (17).  
Butyrate is a potent inducer of cell cycle arrest in cancer cells (41), and this led to the in 
vitro application of butyrate on satellite cells with mixed results as to its benefit at 
promoting myogenesis (27-30).  In satellite cells, HDACs are expressed during 
proliferation so as to maintain muscle specific gene silencing (35).  Not only do HDACs 
remodel the chromatin around muscle specific genes in a repressive way, but HDAC1 is 
known to associate with MyoD and inhibit target gene expression (5).   Neither the 
myopathy or growth models treated with butyrate have investigated the impact on satellite 
cells or HDAC activity.   
 
It has been reported that butyrate may enhance muscle gene expression at different stages 
of myogenesis (27) as well as inhibit the myogenic program (23, 29, 30).  These conflicting 
reports are at odds and further investigation is warranted.  These studies differed in timing 
of butyrate treatment and butyrate concentration.  Given the differing techniques and 
application of butyrate on satellite cells in culture, we investigated the degree to which 
butyrate can alter the myogenic program.  At physiologically relevant concentrations 
butyrate was applied during proliferative and differentiative conditions and satellite cell 






Materials and Methods 
Isolation of satellite cells 
All animal protocols were approved by the University of Maryland-College Park’s 
Institutional Animal Care and Use Committee.  Primary satellite cells were isolated and 
cultured individually from 4 piglets (14±2 days of age) according to a procedure modified 
from Doumit and Merkel (19) and Allen et al. (3).  Briefly, loin muscle was excised, 
trimmed of connective tissue and minced with scissors.  Tissue fragments were digested 
with 1.25mg/ml protease from Streptomyces griseous (Pronase, Sigma-Aldrich, St. Louis, 
MO) for 1h at 37˚C.  Satellite cells were disassociated from tissue fragments by trituration 
and differential centrifugation.  Cells were pre-plated on uncoated 15cm tissue culture 
dishes for 2h (37˚C, 5% CO2) in proliferative growth media (PGM, DMEM + 10% FBS + 
antibiotics- 100U/mL penicillin, 100µg/mL streptomycin, 10µg/mL gentamycin; Gibco) 
and then seeded on tissue cultured treated dishes coated with Poly-L-lysine (100µg/mL 
ddH2O, Sigma-Aldrich) and fibronectin (10µg/mL PBS, Sigma-Aldrich) in proliferative 
growth medium until they reached 50% confluence (37˚C, 5%CO2).  Cells were then 
released with 0.05% Trypsin (Gibco) and plated for our studies.   
 
Cell culture 
Effect of butyrate during proliferative conditions- Satellite cells were seeded at 2,500 
cells/cm2 in PGM on to plates coated with Poly-L-lysine and fibronectin.  After a 24h 
attachment period, complete media changes were made daily and cells received PGM 
supplemented with sodium butyrate (NaBu) at 0mM, 0.1mM, 0.5mM, or 1mM and allowed 





and in vitro proliferation and apoptosis were measured at 24h or 48h after addition of NaBu. 
 
Effect of butyrate during differentiative conditions-  Satellite cells were allowed to 
proliferate in PGM until confluent and then switched to differentiation media (DM, DMEM 
+ 2% horse serum; Gibco + antibiotics) for 96h in the presence of 0, 0.1, 0.5, or 1mM 
NaBu.  Gene expression was measured at all time points during differentiation.  At the 48h 
and 96h time points in vitro apoptosis and immunocytochemistry was measured.          
In vitro proliferation was analyzed at the 24h and 48h proliferative time points using the 
Click-iT EdU Alexa Fluor 488 imaging kit (Molecular Probes).  Satellite cells were pulsed 
for 2h and then fixed and stained according to the manufacturer’s protocol.  The rate of 
apoptosis was also measured during proliferation (48h) and differentiation (48h and 96h) 
using the Click-iT TUNEL Alexa Fluor 594 assay (Molecular Probes) according to the 
manufacturer’s protocol.  
 
Analysis of gene expression  
Total RNA was isolated using the RNAqueous Micro kit (Ambion) and quantified using 
the Quant-iT RiboGreen assay (Molecular Probes) according to the manufacturers’ 
protocols.  Harvested RNA was reversed transcribed with the SuperScript IV First-Strand 
Synthesis System (Invitrogen) and treated with the RNase H to ensure removal of RNA.  
The resulting cDNA was quantified with the Quant-iT OligoGreen assay (Molecular 
Probes).  Total RNA and cDNA quantification were detected on the Synergy HTX 
microplate reader using the Gen 5.0 v3.0 software (BioTek Instruments, Winooski, VT).  





Time PCR Detection System and iQ Multiplex Powermix (Hercules, CA).  Primers and 
probes were designed by Integrated DNA Technologies (Coralville, IA) (Table 2-1).  
Genes of interest were normalized to the reference gene, RPL4, using the 2-∆∆CT method.  
Reactions were amplified for 45sec at 60˚C for 40 cycles.  Analysis and amplification plots 
were executed with the CFX Manager Software (version 3.1, Bio-Rad).   
 
Table 2-1.  Primers and probe sequences used for gene expression analysis by multiplex quantitative RT-
PCR. 
Gene Symbol Gene ID Primer Sequence 5’-3’ Probe and Sequence 5’-3’ 
PAX7 100625823 F: CAGCAAGCCCAGACAGG R: TCGGATCTCCCAGCTGAA (HEX): TTGAGGAGTACAAGAGGGAGAACCCA 
MYOD1 407604 F: CCGACGGCATGATGGATTATAG R: CGACACCGCAGCATTCTT (FAM): AATAGGTGCCGTCGTAGCAGTTCC 
MYOG 497618 F: AGTGAATGCAGTTCCCACAG R: AGGTGAGGGAGTGCAGATT (Texas Red): CAACCCAGGGGATCATCTGCTC 




Satellite cells were fixed in 4% paraformaldehyde in PBS for 15min and permeablized with 
0.1% Triton X-100 in PBS for 20min.  Fixed cells were blocked in 10% goat serum in 
PBST (0.1% Tween-20 in PBS) for 1h at room temperature.  The cells were incubated 
overnight at 4˚C in the primary antibodies diluted in PBST at the following concentrations: 
(1) mouse monoclonal anti-Pax7, 10µg/mL, Sigma-Aldrich; (2) rabbit polyclonal anti-
MyoD1, 5µg/mL, Santa Cruz Biotechnology, Inc., Santa Cruz, CA; (3) mouse monoclonal 
anti-myogenin, 5µg/mL, AbCam, Cambridge, MA; and (4) rabbit polyclonal anti-fast 
myosin skeletal heavy chain (MyHC), 5µg/mL, AbCam.  Primary antibodies were removed 
and incubated with secondary antibodies (AlexaFluor 488 goat anti-mouse IgG and 





Grove, PA) in 1% BSA in PBS for 1h at room temperature.  Nuclei were visualized with 
4’,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich).  Images were visualized on a 
Leica DM5500 with software (Leica Microsystems, Wetzlar, Germany). 
 
Statistical Analysis   
The effect of NaBu treatment on satellite cell behavior was examined using an F-test in 
ANOVA.  In the case of a significant F-test, multiple mean comparisons were analyzed 
using Dunnett’s test.  Proliferation data was examined by regression analysis with linear 
and quadratic contrasts to determine the nature of a dose response.  Four biological 
replicates were included for all comparisons; a probability of P ≤ 0.05 was considered 
significant.  Statistical procedures were analyzed using GraphPad Prism 7 (GraphPad 




Treatment with NaBu reduced proliferation rates the 24h time point (quadratic; R2=.77, 
P<.05), but not the 48h time point (quadratic; R2=.66, P>.05), in a dose-dependent manner 
(Figure 2-1).  After exposure to 0.1, 0.5, or 1mM NaBu for 24h, satellite cell proliferation 
was reduced by 15%, 36%, and 41%, respectively, as compared to the control.  After 48h 
of continuous exposure, the reduction in satellite cell proliferation rates did not exhibit a 
dose response when treated with NaBu; however, proliferation rates were significantly 
reduced by 50% (P<.05) and 64% (P<.01) in the 0.5mM and 1mM treatment groups, 





apparent increase in cells undergoing apoptosis could be observed in any treatment group 



































































Figure 2-1.   Effect of sodium butyrate on proliferation of satellite cells after 24h (A & C) and 48h (B & 
D).  Satellite cells were pulsed with EdU for 2h and allowed to proliferate.  Representative images (top 
row: 0mM; bottom row: 1mM) detecting the newly synthesized DNA in replicating cells (green) and total 
nuclei were counted (blue) and compared (composite).  The percentage of EdU+ cells in the 0mM, control 
treatments, were set at 1 for each animal and number of EdU+ cells of the treatment groups were 
normalized as a proportion thereof within each animal.  At least 300 cells were counted and averaged 
from two technical replicates for each animal.  Values depicted are means with standard error plotted on 
an interpolated quadratic function. 














Relative gene expression and immunocolocalization of Pax7 and the MRFs MyoD and 
myogenin were determined to examine the effect of NaBu on the progression of satellite 
cells through their myogenic lineage.  During proliferation, we found a significant 
reduction (P<0.05) in Pax7 transcript with increasing NaBu concentration at both the 24h 
and 48h time points (Figure 2-3).  Satellite cell expression of MyoD during proliferation 
did differ significantly from the NaBu treatment as compared to the control (data not 
shown).  Localization of these two transcription factors indicated nearly all cells were 
Pax7+/MyoD+ in all NaBu treatments (Figure 2-3).  There was no relative difference among 
treatment groups in myogenin expression or MyoD+/Myogenin+ satellite cells during 
proliferation (data not shown). 
 
Figure 2-2.  Effect of sodium butyrate on apoptosis in satellite cells.  A TUNEL assay was performed to 
determine the rate at which butyrate may be affecting cell apoptosis at 48h of proliferation (image not 
shown) and at the 48h and 96h time points of differentiation (96h time point not shown).  Across all time 
points and all treatments, apoptosis was undetectable.  Images A: 0mM, B: 1mM indicating TUNEL- 
staining.  Images C: Satellite cells treated with DNAse as positive control (TUNEL+, red), D: Negative 
control lacking the TdT (terminal deoxynucleotidyl transferase) enzyme. All images are composite, nuclei 










Untreated satellite cells were then switched to differentiation media after 90% of 
confluence and subjected to the same NaBu treatment regimen for 96h.  Pax7 was reduced 
at the 24hr time point of differentiation, but not significantly as this is when Pax7 
expression is typically reduced.  Myogenin expression was strongly upregulated in the 
0.5mM and 1mM NaBu treatments after 48h of differentiation as compared to endogenous 
expression in the control (P<.05) (Figure 2-4).  The NaBu treatments did not have a 
significant effect on MyoD expression.  Immunostaining for MyoD+/Myogenin+ cells did 
not reveal any significant differences between the treatment groups.  Differentiated cells 
were also immunostained for MyHC, a late stage contractile protein of differentiated 
satellite cells (20), so as to analyze the number of fused cells and myotube formation.  There 
A 
Figure 2-3.  Gene expression and 
immunocolocalization of myogenic proteins 
in response to NaBu during proliferation.  
(A) Pax7 gene expression as determined by 
RT-PCR, expression was normalized to 
RPL4 expression within each animal at 24h 
(2-∆∆Ct) (PGM, Proliferative Growth Media).  
(B) Immunofluorescent staining after 24h of 
proliferation revealed nearly all cells were 
Pax7+/MyoD+ (green/red) for the control 
(0mM) and (C) the treatment groups (1mM, 
other treatments not shown) (nuclei 
visualized with DAPI, blue; bottom right 
panes are merged images).  48h images not 




































was an increase in the number of multinucleated cells with increasing concentrations of 

































Figure 2-4.  Myogenin expression in differentiating satellite cells as 
determined by RT-PCR.  Expression was normalized to RPL4 
expression within animal at each time point (2-∆∆Ct) (DM, 
Differentiation Media).  Inset:  Endogenous expression of myogenin 
































































































































































The progression of satellite cells through their myogenic lineage is a tightly controlled 
process under the regulation of a hierarchal network of transcription factors.  In the present 
study, we examined the ability of the HDAC inhibitor butyrate to alter proliferation and 
differentiation of primary porcine satellite cells in vitro.  While HDAC inhibitors have been 
shown to both enhance and obstruct myogenesis (27-30), our results demonstrate that 
butyrate can accelerate myogenesis through increased upregulation of the MRF myogenin 
during differentiation and an increase in satellite cell fusion.   Our findings also help further 
establish that at low doses, butyrate can serve as a potential effector molecule for muscle 
hypertrophy and regeneration. 
Figure 2-5.  The fusion percentages of differentiating satellite cells 
were assessed by immunostaining for MyHC to determine the 
number nuclei in MyHC+ cells/total nuclei.  Multinucleated (2 or 
more nuclei in the same MyHC+ cell) myotubes were counted and 
compared to total nuclei after 48h and 96h post-differentiation.  
Fusion percentages were calculated and the control was set to 1.  Two 






In concurrence with previous findings, in a dose dependent manner NaBu forced satellite 
cells to exit the cell cycle and slowed the rate of proliferation.  Relative Pax7 expression 
was markedly decreased when treated with NaBu.  When exposed to butyrate, or any other 
HDAC inhibitor, satellite cell expression of Pax7 has yet to be investigated.  While Pax7 
is crucial for the survival, proliferation, and self-renewal of satellite cells (52, 60), over 
expression in activated satellite cells down-regulates MyoD and prevents differentiation 
through an inhibition of myogenin expression (42).  Our results support the assertion that 
Pax7 and myogenin expression are mutually exclusive, whereby butyrate’s negative 
influence on Pax7 expression during proliferation may aid in the upregulation of myogenin 
during differentiation.  The cell culture methods used by Iezzi et al. (27) demonstrate this 
ability of NaBu to enhance satellite cell myogenesis when applied for a 24h period during 
proliferation and then removed when switched to differentiation media; in part, priming 
the satellite cells for differentiation by pulsing with NaBu.  
 
The apparent increase in myogenin expression and satellite cell fusion reinforce the major 
theme, in that butyrate can enhance terminal differentiation.  While not all muscle 
differentiation genes are under the control of myogenin (56), a substantial number of 
sarcomeric, contractile and enzymatic components of muscle require myogenin and cannot 
rely on MyoD or the myocyte enhancer factor 2 (MEF2) family of genes for transcriptional 
activation (16).  Furthermore, almost all satellite cells had begun to express MyHC even if 
they had not yet fused to neighboring cells.  When NaBu was applied to subconfluent cells, 
myogenin expression was upregulated; however, myotube formation was hindered.  The 





treatment with NaBu at reduced confluency may have confounding effects, as seen by Iezzi 
et al. (27).  Inherent to satellite cell fusion and progression through the myogenic program, 
the timing of the differentiation process and the necessity of an in vitro satellite cell niche 
may be the reason that such incongruity on the definitive role that butyrate plays in 
myogenesis. 
 
Butyrate acts by inhibiting the chromatin remodeling activity of class I and II HDACs, 
ultimately leading to hyperacetylated histones and a relaxed chromatin structure (17). 
HDACs have also been implicated in associating with both the MRF and MEF2 family of 
genes and repressing their activity (24, 35).  Also of note, in undifferentiated satellite cells, 
MyoD is known to associate with class I HDACs which represses myogenesis (47).  This 
underscores our assertions that butyrate enhances terminal differentiation by inhibiting the 
repressive HDACs.  However, forcing satellite cells to differentiate too early in the 
myogenic program results in poor myotube formation as was also indicated by our results.  
Under normal conditions, the acetylation of MyoD only takes place when satellite cells are 
triggered to differentiate (32), explaining the observed increase in myogenin expression 
without a parallel increase in MyoD expression.  NaBu may have accelerated the rate at 
which MyoD was acetylated while also preventing the repressive action of MyoD-recruited 
HDACs.  To what degree of interaction MEF2 and myogenin may have warrants further 
investigation, but in sum, the synergistic effects of unrepressed MyoD-mediated 
transcriptional activation of both myogenin and MEF2 appears to hasten and amplify 






Our results demonstrate that at low (0.1-1mM) concentrations of NaBu, primary satellite 
cell behavior is altered.  Previous in vitro studies (27, 29, 30) have exposed satellite cells 
to concentrations of butyrate at 5mM or greater.  From a translational aspect, exposing 
satellite cells in vivo to this level of butyrate becomes a significant technical challenge in 
non-ruminant species.  It should also be taken into consideration the clearance rate of 
butyrate once it reaches peripheral circulation.  Egorin et al. (22) found that intravenous 
dosing of sodium butyrate was unable to maintain plasma butyrate concentrations above 
1mM for more than 30min in mice.  Similarly, orally administered butyrate is rapidly 
metabolized, has a short plasma half-life and even the salt form of the volatile fatty acid 
produces a strong and an unpleasant odor, making it unsuitable for maintaining effective 
butyrate plasma concentrations.  Tributyrin, a butyrate prodrug, which has 3 butyrate 
molecules esterified to a glycerol backbone, has shown to be a suitable alternative to orally 
ingested butyrate, maintaining concentrations above 0.1mM for 3h (13, 15, 22).  
Collectively, this warrants a more detailed investigation into butyrate’s influence on 
myogenesis and the satellite cell myogenic program in vivo.  
  
In conclusion, we examined to what effect varying concentrations of the HDAC inhibitor 
NaBu have on satellite cells during their myogenic lineage.  In vivo and in vitro 
experimentation models treated with butyrate have had positive results on myogenesis, but 
it is unclear from these studies as to how the myogenic program is affected.  Our work 
presents a detailed view of the potential mechanism through which butyrate alters satellite 
cell behavior and programming at physiologically relevant doses.  Conversely, we note that 





formation, and that inherent satellite cell characteristics must be taken into account when 
developing an appropriate cell culture system.  We offer that tributyrin may serve as a 
viable vehicle to expose satellite cells in vivo to requisite amounts of butyrate in order to 
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Chapter 3: Dietary tributyrin, a HDAC inhibitor, promotes muscle 




Muscle growth and repair rely on two main mechanisms, myonuclear accretion and 
subsequent protein accumulation.  Altering the ability of muscle resident stem cells 
(satellite cells) to progress through their myogenic lineage can have a profound effect on 
lifetime muscle growth and repair.  The use of the histone deacetylase (HDAC) inhibitor, 
butyrate, has had positive outcomes on the in vitro promotion of satellite cell myogenesis.  
In animal models, the use of butyrate has had promising results in treating myopathic 
conditions as well as improving growth efficiency, but the impact of dietary butyrate on 
satellite cells and muscle growth have not been elucidated.  We investigated the impact of 
tributyrin, a butyrate pro-drug, on satellite cell activity and muscle growth in a piglet 
model.  Satellite cells from tributyrin treated piglets had altered myogenic potential, and 
piglets receiving tributyrin had a ~40% increase in myonuclear accretion after 21d, 
indicating the potential for enhanced muscle growth.  To assess muscle growth potential, 
piglets were supplemented tributyrin (0.5%) during either the neonatal phase (d1-d21) 
and/or the nursery phase (d21-d58) in a 2x2 factorial design. Piglets who received 
tributyrin during the neonatal phase had improved growth performance at the end of the 
study and had a ~10% larger loin eye area and muscle fiber cross-sectional area.  Tributyrin 
treatment in the nursery phase alone did not have a significant effect on muscle growth or 
feed efficiency.  These findings suggest that tributyrin is a potent promoter of muscle 







Post-natal muscle growth and repair rely on the ability of satellite cells, muscle resident 
stem cells, to activate, proliferate, and fuse into growing myofibers (16, 53).  During the 
neonatal stage of life, the fractional rate of protein synthesis contributing to muscle growth 
is highest (13), marked by increased satellite cell activation, proliferation (2, 10), and 
myonuclear accretion (52).  It has also been found that interventions that target satellite 
cells at this age can have lifetime effects on muscle growth and regenerative capacity (1, 
8).  The myogenic program is under the regulation of a hierarchy of transcription factors 
that govern satellite cell lineage fate (51) and these regulators have proven to be prospective 
targets in promoting muscle growth (5).  It has recently been suggested that histone 
deacetylase (HDAC) inhibitors may serve as a viable tool to epigenetically alter satellite 
cell behavior (41, 54).  Butyrate is a potent and broad-spectrum inhibitor of HDACs that 
has shown to be beneficial at treating models of muscle pathology (40, 57), but its effects 
on satellite cell activity (26, 28, 32) is controversial.  Dietary butyrate, along with tributyrin 
(a butyrate pro-drug), have had positive effects on growth performance (as measured by 
growth rate and efficiency of growth per unit of feed)  (45, 47, 61), but these findings have 
been attributed to improved intestinal and digestive functions (14, 23, 25, 29, 30).  While 
the favorable use of dietary butyrate seems clear, investigating whether it could be used as 
a muscle growth promoter would have profound impacts for human health and animal 
production.    
 
Post-natal muscle growth and protein accretion is considered a hypertrophic event, as the 





satellite cells and their fusion with growing muscle fibers govern the rate of muscle growth 
and regeneration (5).  As expected, due to their central role in lifetime muscle growth and 
regeneration, the activity of satellite cells is tightly regulated via the expression of multiple 
transcription factors.  The paired-homeobox transcription factor Pax7 is universally 
expressed in satellite cells and allows for satellite cell proliferation by preventing 
precocious differentiation (44, 53).  Additionally, Pax7 plays a role in the regulation of the 
downstream network of myogenic regulatory factors (MRFs), specifically myogenic 
differentiation 1 (MyoD) and myogenin (42). Changes in the Pax7 and MRF expression 
patterns have been shown to regulate satellite cell commitment fate, where a decrease in 
the Pax7:MyoD ratio leads to terminal differentiation and myogenin expression (43).  
Upregulating Pax7 expression prevents myogenin expression and allows for satellite cells 
to either self-renew or enter into a quiescent state (42).  Activation of MyoD is necessary 
for proliferating satellite cells to continue through their myogenic lineage and to trigger 
terminal differentiation of myoblasts (38).  The downstream target of MyoD, myogenin, is 
necessary for fiber development embryonically and for post-natal muscle growth (22, 56).  
Defects in the myogenin gene lead to pools of undifferentiated satellite cells without an 
apparent effect on the expression of MyoD.  The alteration of the expression and timing of 
these myogenic regulatory genes has been presented as a practical means to increase 
muscle hypertrophy and regeneration (6, 41). 
 
Epigenetic modifiers that inhibit HDACs in myoblasts are gaining increasing interest in 
the fields of muscle growth and regeneration (54).  The beneficial effects of HDAC 





models (see (36) for review).  Only recently has it been suggested that inhibiting HDACs 
could alter myogenic programming (37).  When HDACs are expressed in undifferentiated 
satellite cells, they bind to MyoD and the late stage MRF, myogenin, is not expressed (37).  
In culture, the HDAC inhibitors have shown to increase myotube hypertrophy without an 
increase in satellite cell proliferation (27).  Sodium butyrate has also had positive effects 
at influencing satellite cell fusion and increasing myotube hypertrophy in culture (26).   
 
The 4-carbon fatty acid, butyrate, is an inhibitor of many HDACs (11, 12).  Butyrate is 
produced naturally in the body from the fermentation of dietary fiber and has been 
examined as an antitumor agent since the 1970’s (39, 48).  There have been conflicting 
reports on the effect of in vitro application of butyrate on satellite cell behavior, from 
enhancing muscle gene expression at different stages of myogenesis (26) as well as 
inhibiting some parts of the myogenic program (20, 28, 32).  Within the animal production 
industry, butyrate has been used as an aid in improving intestinal health (23, 61) and growth 
performance through inclusion as the more palatable version, tributyrin, in the diet (25, 
30).  While muscle hypertrophy through satellite cell programming has not been elucidated, 
butyrate has had promising effects on muscle healing in some injury models (18, 57, 58).  
Using neonatal and nursery piglets as model of rapid muscle growth, we characterized the 
effects of butyrate on satellite cell activity and their myogenic progression.  We 
hypothesize that supplementation of dietary tributyrin may serve as an effective promoter 






Materials and Methods 
Animals, diets and experimental protocol 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
of the University of Maryland-College Park.  In two animal feeding trials, we investigated 
the effects of tributyrin supplementation on muscle growth during both the neonatal (birth 
to 21-days of age) and nursery (22 to 58-days of age) phases of growth.  During first animal 
feeding trial, tributyrin was supplemented at two different levels for 21 days to establish 
an inclusion rate for the second animal feeding trial that would extend into the nursery 
phase.  
 
Study 1- To assess the impact of dietary tributyrin inclusion on in vivo satellite cell 
programming, 30 cross-bred female piglets (24±6h old; 1.79±.25kg body weight) were 
assigned to 1 of 3 treatments (n=10/group) and balanced by body weight and litter.  Piglets 
received either a standard commercial milk replacer formula (Advance Liqui-Wean, Milk 
Specialties Co., Dundee, IL) where 175g of dry milk replacer was reconstituted in water to 
1kg total formula (C), or the milk replacer formula supplemented with 0.25% (T.25) or 0.5% 
(T.5) total butyric acid in the form of spray dried tributyrin (AviPremiumD, Vetagro SpA, 
Reggio Emilia, Italy).  Tributyrin inclusion was on a dry matter basis and diets across 
treatments were made isoenergetic by the addition coconut oil.  Piglets were housed 
individually and received formula every 2hrs (0900-2300) at a limit-fed rate to match sow 
reared growth.  One piglet from T.5 was removed from the study due to non-treatment 
related health issues.  Body weight and feed intake were recorded daily for the duration of 





bromodeoxyuridine (BrdU, Sigma Aldrich, St. Louis, MO) 18h prior to euthanasia to 
determine in vivo proliferation of satellite cells.  Longissumus dorsi (LD) muscle was used 
for all tissue analysis and satellite cell isolation.   
 
After the 21-day neonatal feeding trial, LD was snap frozen in liquid N2 for total DNA, 
protein abundance, and gene expression analysis.  Total muscle protein extractions were 
performed on ice in NP-40 buffer (20mM Tris-HCl pH 8, 125mM NaCl, 1% NP-40, 2 mM 
ethylenediaminetetra-acetic acid (EDTA), 10% glycerol) for 30 min containing cOmplete 
protease inhibitor and PhosSTOP phosphatase inhibitor cocktails (Roche, Basel, 
Switzerland).  Insoluble material was pelleted by centrifugation at 15,000g for 15 min at 
4°C.  Protein concentrations were determined using BCA assays (ThermoFisher Scientific, 
Waltham, MA).  
 
Total DNA was extracted (DNeasy, Qiagen), fluorescently quantified (Quant-iT dsDNA 
assay kit) and compared to the total protein content of the LD muscle.  Total RNA was 
isolated by homogenization using tri-reagent (ThermoFisher Scientific) with phase 
separation achieved by chloroform wash.  RNA was precipitated with 70% ethanol and 
transferred to RNeasy spin column and purified according to the manufacturers protocol 
(Qiagen). 
 
For immunohistological analysis to determine fiber cross-sectional area (FCA), LD 
samples were embedded in a 1:1 10% tragacanth gum OCT mixture and snap frozen in 





Superfrost Plus slides for immunostaining.  FCA and fiber number were determined by 
anti-dystrophin staining of the sarcolemma described below.   
 
Study 2- We investigated the impact of continual dietary tributyrin inclusion through the 
nursery phase of growth in a 2 x 2 factorial treatment structure.  Piglets, 30 cross-bred 
females (24±6h old; 1.54±.32kg body weight), were either fed either a standard commercial 
milk replacer formula (C, n=15) or the milk replacer formula supplemented with 0.5% total 
butyric acid in the form of spray dried tributyrin (T, n=15) (as performed above) for 21-
days.  Piglets were then weaned at 22-days of age and crossed into their respective nursery 
phase dry diet: either commercial dry nursery control diet (CC or TC; n=6/group) 
(TechMix, Stewart, MN) or a control diet supplemented with 0.5% total butyric acid in the 
form of spray dried tributyrin (CT or TT; n=9/group) (AviPremiumD, Vetagro SpA).  The 
control dry diet was supplemented with microencapsulated palm oil to ensure equivalent 
energetics to the treatment diet.  Piglets were fed ad libitum and had access to ad libitum 
water.  Three piglets (1 from the TC group and 2 from the TT group) were removed from 
the study for failing to wean.  After weaning, body weight and feed intake were recorded 
weekly for the duration of the 37-day nursery feeding trial.  At the end of the 58-day feeding 
trial, LD muscle was removed at the 12th rib to measure total loin area, evaluate gene 
expression, and for immunohistochemical analysis to determine FCA (as described above). 
 
Satellite cell isolation and culture 
Satellite cells from the neonatal piglets (Study 1) were isolated according to a procedure 





excised from neonatal piglets after their prescribed 21-day feeding regimen, trimmed of 
connective tissue, and minced with scissors.  Tissue fragments were digested with 
1.25mg/ml protease from Streptomyces griseous (Pronase, Sigma-Aldrich) for 1h at 37˚C.  
Satellite cells were disassociated from tissue fragments by trituration and differential 
centrifugation.  Cells were pre-plated on uncoated 15cm tissue culture dishes for 2h (37˚C, 
5% CO2) in proliferative growth media (PGM, DMEM + 10% FBS + antibiotics- 100U/mL 
penicillin, 100µg/mL streptomycin, 10µg/mL gentamycin; Gibco) and then seeded on 
tissue cultured treated dishes coated with Poly-L-lysine (100µg/mL ddH2O, Sigma-
Aldrich) and fibronectin (10µg/mL PBS, Sigma-Aldrich) in PGM until they reached ~50% 
confluence (37˚C, 5%CO2) or analyzed for in vivo proliferation (described below).  Cells 
were then released with 0.05% Trypsin (Gibco) and plated for our studies.   
 
The effect of dietary tributyrin inclusion (0.25% and 0.5%, n=10) effect on ex vivo satellite 
cell dynamics was analyzed under proliferative and differentiative conditions.  Satellite 
cells were seeded at 2,500 cells/cm2 in PGM on to plates coated with Poly-L-lysine and 
fibronectin.  After a 24h attachment period, satellite cells were given 48hrs in PGM and 
then induced to differentiate (DM, DMEM + 2% horse serum; Gibco + antibiotics) for an 
additional 72h with complete media changes daily.  Total RNA was isolated (RNeasy, 
Qiagen) at each 24h time point for gene expression analysis.  Satellite cell fusion was 
measured at 48h post-differentiation by immunostaining.  
 
In vitro proliferation was analyzed 24h after plating using the Click-iT EdU Alexa Fluor 





fixed and stained according to the manufacturer’s protocol.  In vivo proliferation was 
assayed by identifying proliferating cells with BrdU.  Satellite cells that had been direct 
plated were fixed 4% paraformaldehyde and permeablized in 0.1% Triton X-100 (Sigma-
Aldrich) in PBS.  Antigen retrieval was performed with 2N HCl for 45m at 37˚C, acid was 
buffered for 10m with sodium tetraborate, and cells were blocked with 10% goat serum in 
PBST.  Satellite cells were incubated with anti-BrdU (6µg.mL, Bio-Techne, Minneapolis, 
MN) overnight at 4˚C.  Nuclei were visualized with 4’,6-diamidino-2-phenylindole (DAPI) 
(Sigma-Aldrich).  Images were visualized on a Zeiss AxioObserver Z.1 and analyzed with 
ZenPro automated image analysis suite (Carl Zeiss AG, Oberkochen, Germany).      
 
Western blot analysis 
Protein from neonatal LD muscle homogenate was quantified for total protein content by 
BCA assay (Pierce) and subjected to western blotting.  Equal amounts of protein were 
electrophoresed and separated on 7.5% Mini-PROTEAN TGX Precast Gels, transferred to 
an Immun-Blot PVDF Membrane (Bio-Rad, Hercules, CA) and stained with SimplyBlue 
SafeStain (ThermoFisher Scientific) to ensure protein transfer.  The membrane was then 
incubated at 4˚C overnight with the following the primary antibodies at a 1:1000 dilution, 
rabbit anti-phospho mTOR (Ser-2448) and rabbit anti-phospho-AMPKα (Thr-172) (Cell 
Signaling Technology, Danvers, MA).  Membranes were incubated for 1h with horseradish 
peroxidase-conjugated goat anti-rabbit secondary antibody (Jackson Immunoresearch, 
West Grove, PA), and developed with SuperSignal West Pico Chemiluminescent Substrate 
Kit (ThermoFisher Scientific).  Densitometry analysis was performed using a ChemiDoc 





by reprobing with anti-AMPKα and anti-mTOR antibodies (1:1000, Cell Signaling 
Technology). Optical density was normalized to a pooled treatment sample as a loading 
control. 
 
Analysis of gene expression  
Total RNA isolated from neonatal piglet LD muscle and satellite cells were quantified 
using the Quant-iT RiboGreen assay (Molecular Probes) according to the manufacturer’s 
protocol.  Harvested RNA was reversed transcribed with the SuperScript IV First-Strand 
Synthesis System, using equal concentrations of OligodT(20) and random hexamers 
(Invitrogen) and treated with the RNase H to ensure removal of RNA.  The resulting cDNA 
was quantified with the Quant-iT OligoGreen assay (Molecular Probes).  Total RNA and 
cDNA quantification were detected on the Synergy HTX microplate reader using the Gen 
5.0 v3.0 software (BioTek Instruments, Winooski, VT).  cDNA was used for multiplex 
qRT-PCR using Bio-Rad’s CFX96 Touch Real-Time PCR Detection System and iQ 
Multiplex Powermix.  Analysis of gene expression (Pax7, MyoD, myogenin) and 
amplification plots were executed with the CFX Manager Software (version 3.1, Bio-Rad).  
Primers and probes for the gene expression analysis were designed by Integrated DNA 
Technologies (Coralville, IA) (Table 3-1).  After optimization, a 2:1 primer-to-probe ratio 
was utilized for genes of interest while a 1:1 ratio was used for the reference gene, RPL4.  









Table 3-1.  Primers and probe sequences used for gene expression analysis by multiplex quantitative RT-
PCR. 
Gene Symbol Gene ID Primer Sequence 5’-3’ Probe and Sequence 5’-3’ 
PAX7 100625823 F: CAGCAAGCCCAGACAGG R: TCGGATCTCCCAGCTGAA 
(HEX): 
TTGAGGAGTACAAGAGGGAGAACCCA 
MYOD1 407604 F: CCGACGGCATGATGGATTATAG R: CGACACCGCAGCATTCTT 
(FAM): 
AATAGGTGCCGTCGTAGCAGTTCC 
MYOG 497618 F: AGTGAATGCAGTTCCCACAG R: AGGTGAGGGAGTGCAGATT 
(Texas Red): 
CAACCCAGGGGATCATCTGCTC 






Satellite cell cultures and LD muscle sections were immunostained to determine myotube 
formation and FCA respectively.  Satellite cells were analyzed for the expression of the 
contractile protein myosin heavy chain (MyHC) after 48h of differentiation.  Satellite cells 
were pre-fixed and nursery LD muscle sections were post-fixed in 4% paraformaldehyde 
and permeablized with Triton X-100.  Samples were blocked with 10% goat serum in PBST 
(0.1% Tween-20 in PBS) for 1h at room temperature.  Cells and slides were incubated 
overnight at 4˚C with primary mouse monoclonal anti-MyHC at 10µg/mL (Roche) or anti-
dystrophin at 5µg/mL (R&D Systems, Minneapolis, MN) respectively.  Primary antibodies 
were removed and incubated with the secondary antibody (AlexaFluor 488 goat anti-mouse 
IgG at 1:500 dilution, Jackson Immunoresearch) in 5% goat serum for 1h at room 
temperature.  Myotube formation and FCA images were collected with Zeiss AxioObserver 
Z.1 and analyzed with ZenPro automated image analysis suite (Carl Zeiss AG). 
 
Statistical Analysis   
Study 1- The effects of tributyrin concentration on the response variables were analyzed 






Study 2-Data were analyzed as a two-way ANOVA using the PROC MIXED procedure in 
SAS (version 9.3; SAS Institute Inc., Cary, NC).  Milk replacer treatment, dry nursery 
dietary treatment, and their interaction were analyzed as fixed effects while covariate(s) 
(initial body weight and/or weaning weight) were analyzed as random effects in the 
MIXED procedure of SAS (9.3).   
 
In the case of a significant F-test, multiple mean comparisons were analyzed using a 
Tukey’s adjustment.  A probability of P ≤ 0.05 was considered significant and a P-value 
between 0.05 and 0.10 (0.05 < P ≤ 0.10) was considered a trend.  Data reported as least 
square means ± SEM.   
 
Results 
Tributyrin inclusion on growth performance   
Study 1-After the 21-day, neonatal feeding trial, there was no effect of treatment on final 
body weight, average daily gain (ADG), or feed efficiency.  There was a nonsignificant 
decrease in feed intake in the T.5 group.  LD muscle was harvested to analyze treatment 
effects on cellular mechanisms of muscle growth rate.  Tissue homogenate was examined 
for total protein and DNA content to assess the DNA:protein as a measure of myonuclear 
accretion (Figure 3-1).  There was a significant increase in the DNA:protein in the T.5 group 
(5.5±0.5mg/g, DNA/protein) compared to the other two treatment diets  
(T.25=4.1±0.4mg/g; C=3.8±0.5mg/g) (P<.05).  There was no treatment effect on the ratio 





blotting (data not shown).  Based on these findings, we supplemented the milk replacer 
with 0.5% tributyrin for the nursery feeding trial in order to investigate the potential for 




Study 2-At the end of the 58-day feeding trial (neonatal + nursery), there was a significant 
increase in final body weight and ADG in animals that received tributyrin in the milk 
replacer before weaning (TT and TC) compared to animals that received control milk 
replacer diet (CC and CT) (P<.05; Table 3-2).  After completion of the trial, piglets treated 
with tributyrin during the neonatal phase (D1-D21) weighed 8% more than the control 
piglets, 30.8±0.6kg and 28.4±0.6kg, respectively, and had a 9% increase in their ADG 
(659±17g compared to the control 603±16g).  There were no treatment effects seen in final 
body weight or feed efficiency between the four nursery diet treatment comparisons.  Loin 
area and FCA from the piglets treated with tributyrin during the neonatal phase was 
significantly larger compared to those piglets that did not receive tributyrin in their milk 
replacer (P<.05; Figure 3-2A).  At the end of the 58-day feeding trial, piglets supplemented 
with tributyrin during the neonatal period had a loin area of 25.3±.7cm2 compared to the 
control piglets, 22.7±.6cm2.  Similarly, muscle histology sections stained with anti-
A B 
Figure 3-1.  Total protein and DNA were extracted from Longissimus dorsi muscle of piglets fed either 
a basal milk replacer (n=10), or the milk replacer supplemented with 0.25% (T.25, n=10) or 0.5% (T.5, 
n=9) tributyrin for 21 days.  (A) Protein and DNA concentrations in LD muscle tissue.  (B) Bar graph 






dystrophin (Figure. 3-2) revealed a 25% increase in the FCA of TT and TC piglets 
(1790±120µm2) compared to CC and CT piglets (1420±60µm2) (P<.05; Figure 3-2). 
 
 
Table 3-2. Effects of tributyrin supplementation during neonatal and nursery phases on growth 
performance. 
 Treatments*†  P§ 
 CC CT TC TT SEM Milk Dry Milk X Dry* 
n 6 9 5 7     
         
Initial Body Weight (kg) 1.6 1.5 1.4 1.6 0.06 ----- ----- -----       
Weaning Weight (kg) 6.4 6.3 5.9 6 0.1 0.11 ------ -----       
Final Body Weight (kg) 29.6
 29.3 30.4 29.6 1.1 0.03 0.66 1.00 
      
Post-weaning Average Daily Gain (g) 627 618 658 641 28 0.03 0.66 0.98       
Feed Efficiency After Weaning‡ 
1.41 1.41 1.37 1.41 0.04 0.37 0.52 0.99 
      
*- Value represented as least square means of main effects 
†- CC (milk replacer control; nursery control), CT (milk replacer control; nursery diet with tributyrin), TC 
(milk replacer with tributyrin; nursery control diet), and TT (milk replacer with tributyrin; nursery diet with 
tributyrin). 
‡- Feed efficiency = Average daily feed intake/average daily gain (day 22-58) 























Satellite cell myogenesis 
Satellite cells were harvested from neonatal piglets after 21d of milk feeding with (T.25 or 
T.5) or without (C) tributyrin supplementation.  There was no treatment effect on in vivo or 
in vitro satellite cell proliferation, as assessed by BrdU and EdU staining, respectively.  

































C Control Tributyrin 
Figure 3-2.  At 58d of age, cross section of Longissimus dorsi (LD) muscle was taken at the 12th rib and 
utilized for immunohistochemical analysis to determine fiber cross-sectional area (FCA).  Values 
depicted are based off pooled neonatal control (C, n=12) or tributyrin (T, n=12) treatment groups.  (A) 
The cross-sectional area of the LD at the 12th rib (loin eye).  (B)  LD muscle FCA as determined by 
immunohistochemistry.  (C) Immunohistochemical analysis of FCA of the LD muscle.  Muscle fibers 
were cryosectioned and stained with anti-dystrophin to visualize sarcolemma (green), >400 fibers/animal 
were counted using Zeiss ZEN Pro automated image analysis.  Nuclei were visualized with DAPI.  






differentiate with gene expression analyzed every 24h to determine myogenic progression.  
Throughout differentiation, there was an average 7-fold (T.25; P<.01) and 4-fold (T.5; 
P<.05) increase in the expression of the late stage MRF myogenin in satellite cells from 
those animals treated with tributyrin compared to control animals (Figure 3-3).  There was 
a not a significant change in Pax7 or MyoD expression in satellite cells from treated 
animals compared to the control animals (data not shown).  When LD muscle sections of 
neonatal piglets from study 1 were analyzed for myogenic gene expression, a similar trend 
was revealed.  Myogenin was upregulated 1.4-fold in the T.25 group compared to the control 
(P<.10) without changes in Pax7 or MyoD expression (Figure 3-4).  To further examine 
the effect of tributyrin on ex vivo satellite cell myogenesis, myotube formation was 
determined 48h after satellite cells were induced to differentiate (Figure 3-5).  There was a 
1.7-fold increase in the number of MyHC+ fused nuclei from T.25 animals compared with 









Figure 3-3.  Myogenin gene expression in cultured satellite cells from neonatal piglets treated with either 
control diet (n=10), or a control diet supplemented with 0.25% (T.25, n=10) or 0.5% (T.5, n=9) tributyrin 
for 21 days.   After induced to differentiate, total RNA was harvested and myogenin expression was 
quantified by RT-PCR. Expression was normalized within animal to RPL4 at each time point.  Bars not 

















































































Figure 3-4.  Total RNA was harvested from Longissiumus dorsi muscle from neonatal piglets treated 
with either control diet (n=10), or a control diet supplemented with 0.25% (T.25, n=10) or 0.5% (T.5, n=9) 
tributyrin for 21 days.  Gene expression of Pax7 and the myogenic regulatory factors MyoD and myogenin 
(MyoG) was measured by quantitative RT-PCR.  Expression was normalized within animal to RPL4.  
Bars not sharing superscripts showed a trend, P<0.10.   





















Figure 3-5.  Satellite cells harvested from neonatal piglets treated with a control milk replacer diet (n=10), 
or a control diet supplemented with 0.25% (T.25, n=10) or 0.5% (T.5, n=9) tributyrin for 21-days were 
induced to differentiate for 48h.  (A) Representative images of immunofluorescently stained myotubes 
with anti-MyHC (green).  Nuclei were visualized with DAPI and counted using Zeiss ZEN Pro automated 
image analysis.  (B) Bar graph depicting the fusion percentages (≥2 nuclei expressing MyHC/total nuclei) 
in satellite cells from those animals treated with either control diet, or a control diet supplemented with 







The benefits of dietary inclusion of butyrate or tributyrin on animal health (21, 24, 45, 47) 
and growth performance (4, 31, 33, 46) have been demonstrated; however, the role that 
butyrate has on the mechanisms behind muscle growth has yet to be elucidated.   In the 
present study, we examined the ability of dietary tributyrin to enhance muscle hypertrophy 
and its effect on satellite cell programming.  Our results demonstrate that early life 
supplementation with tributyrin can promote muscle growth through increased satellite cell 
myogenic potential. 
 
The objective of study 1 was to assess what dietary tributyrin inclusion level is necessary 
to impact muscle growth parameters.  Also, satellite cells were harvested from the neonatal 
animals and we investigated the effect of tributyrin supplementation on in vivo and ex vivo 
satellite cell programming.  At the completion of study 1, the results of tributyrin inclusion 
during neonatal feeding were suggestive that an inclusion rate of tributyrin at 0.5% in study 
2 may improve muscle growth through enhanced myonuclear accretion. 
 
Studies have revealed the beneficial performance and growth effects of butyrate and 
tributyrin supplementation, all the while linking these positive results to an enhanced 
trophic status of the GI tract.  Tributyrin provides an efficient means to deliver butyrate to 
systemic circulation for a sustained duration (19).  Our results indicate that butyrate may 
act as a molecular signal, with a direct effect on satellite cell myogenesis.  Our primary 
objective was to determine the effect of tributyrin supplementation on muscle growth at 





regeneration are dependent upon satellite cell activation and proliferation followed by 
consequent differentiation and fusion into the growing myofiber (13).  After being fed a 
milk replacer supplemented with tributyrin for 21d, piglets had an increase in total DNA 
content and the DNA:protein.  While there were no differences in weight gain at the end 
of the neonatal feeding trial, an increase of almost 40% in total DNA content and the 
DNA:protein ratio suggest an amplification of myonuclear accretion and a propensity for 
enhanced muscle growth (9).  Secondary to myonuclear accretion is the subsequent protein 
synthesis and muscle fiber hypertrophy.  During the neonatal feeding trial, piglets were 
limit-fed to match normal, sow reared growth.  Given this feeding regimen, it is possible 
that the piglets were limited in amino acid availability for maximal protein synthesis.  
While it seems that tributyrin supplementation altered satellite cell behavior, there did not 
appear to be any changes in the mTOR signaling pathway, which governs protein synthesis 
(7) and has shown regulate satellite cell fusion machinery (55).  In intestinal epithelial cells, 
butyrate has been shown to reduce the amount of phospho-AMPK which is known to 
inhibit mTOR (60); however, we did not see any differences by tributyrin treatment.  The 
time required for the accumulated myonuclei to synthesize protein and contribute to the 
growing fiber may not have been sufficient to realize increased muscle hypertrophy.  These 
results imply that prolonged, post-weaning ad-libitum feeding in the nursery would be 
necessary to assess whether dietary tributyrin inclusion would effectively promote muscle 
growth.  
 
Neonatal piglets were once again fed a milk replacer supplemented with 0.5% tributyrin 





the nursery feeding trial, animals that had received tributyrin supplementation in their milk 
had a significant increase in ADG and final body weight.  Interestingly, there was not a 
treatment effect with regards to nursery diet.  These results are similar to those obtained by 
Le Gall et al. (30), where those animals that had received butyrate during milk feeding had 
enhanced growth, but the authors again attribute the increase in growth to increased feed 
digestibility and increased feed intake.  Our data showed no differences in feed efficiency, 
and feed intake was reduced in both of the groups that received tributyrin during their 
respective stages.  Butyrate supplementation has been associated with decreased feed 
intake while on treatment diets in other studies (24, 31); there is also a body of evidence 
linking mild ketosis with decreased appetite and increased satiety through unknown 
mechanisms (49).  It may be that exogenous supplementation of butyrate induces a mild 
ketosis of which decreases overall feed intake and may confound the beneficial effects of 
tributyrin supplementation pre-weaning.  However, the positive effects of tributyrin 
supplementation in the piglet milk replacer resulting in an increase in growth performance 
(Final BW = 8%, ADG = 9%) and muscle growth (Loin area = 11%, FCA = 25%) were 
unmistakable after piglets had reached the end of the nursery feeding. 
 
We found that the hypertrophic benefit of tributyrin supplementation altered satellite cell 
behavior and enhanced terminal differentiation.  The increase in myogenin expression 
found in the LD muscle of the tributyrin treated neonatal piglets may be indicative of 
satellite cells beginning to differentiate quicker and fuse into present myofibers (59).  This 
was marked by the enhanced terminal differentiation seen in the ex vivo satellite cell 





increase in the proportion of those cells expression the contractile protein MyHC. This was 
associated with the increased upregulation of myogenin after satellite cell cultures were 
induced to differentiate.  Although there were no noticeable treatment effects on either in 
vivo or ex vivo satellite cell proliferation, this is noteworthy due to butyrate’s ability to halt 
cell proliferation seen in satellite cell culture experiments (26, 32).  These results indicate 
that the increased myonuclear content may not come from a significant increase in the 
proliferative potential of satellite cells, but rather a temporal acceleration of the 
differentiation process.  The lack of differences seen in the in vivo proliferation of satellite 
cells also suggests that tributyrin’s effect on satellite cell behavior may be most salient at 
the earliest stages of life. 
 
The differences in gene expression and myogenic potential displayed in the satellite cell 
cultures from the tributyrin treated groups also provides acceptance that tributyrin, and its 
ensuing metabolite butyrate, may be serving as an epigenetic modifier of satellite cell 
behavior (54).  The HDAC inhibitory properties of butyrate may be leading to improved 
muscle differentiation through histone modifications that result in increased myogenin 
expression.  This compliments findings that decreased HDAC activity has resulted in 
increased acetylation of non-histone proteins, such as MyoD, which is necessary for 
myogenesis and promotes myogenic differentiation (17, 34, 35).  In this regard, it appears 
that dietary tributyrin may serve as a viable inhibitor of HDACs for pharmacological 






Using a neonatal piglet model of muscle growth, we have shown that early dietary inclusion 
of the butyrate prodrug, tributyrin, resulted in an increase in muscle mass by muscle fiber 
hypertrophy.  Our findings also indicate that the accelerated muscle growth triggered by 
tributyrin is due to increased myonuclear accretion and subsequent myofiber hypertrophy.  
Supplementing tributyrin in the milk replacer formula of neonatal piglets resulted in 
enhanced muscle growth driven by enhanced satellite cell myogenesis.  Contradictory with 
some previous findings (30, 46), dietary supplementation of tributyrin to the older weaned 
pigs did not increase muscle growth or improve growth performance.  This suggests that 
there is a window of opportunity to utilize tributyrin to impact muscle growth via 
alterations in satellite cell activity and that early-life interventions with tributyrin may be 
able to ameliorate deficits in muscle growth caused by limitations in the myogenic activity 
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Chapter 4: The HDAC inhibitor butyrate primes satellite cells for 





Satellite cells (SC) are a heterogeneous population of muscle resident stem cells that are 
responsible for postnatal muscle growth and repair.  With the investigation into the 
genomic regulation of satellite cell fate, we now have an idea as to how the epigenome 
governs SC activation, proliferation, and differentiation.  Interestingly, histone deacetylase 
(HDAC) inhibitors have proven to be effective at enhancing the SC myogenesis, but their 
precise mode of action in altering the epigenetic landscape of SC remains undetermined.  
Our objective was to determine how a HDAC inhibitor, butyrate, promotes myogenic 
differentiation.  Neonatal piglets were fed a standard milk replacer or one supplemented 
with 0.5% spray dried Tributyrin (TB), a butyrate pro-drug.  Satellite cells from TB 
supplemented piglets showed a decrease in the expression of EZH2 (enhancer of zeste 
homolog 2), the methyltransferase subunit of the PRC2 (polycomb repressive complex 2) 
ex vivo.  SC ChIP-Seq analysis revealed that TB treatment resulted in a global reduction of 
the H3K27me3 repressive chromatin mark, specifically around those sites associated with 
genes involved in myogenic differentiation, negative regulation of cell proliferation, and 
micro-RNAs normally upregulated during differentiation.  SC were transfected with 
siRNA targeting EZH2, treated with 0.5mM butyrate, or both to determine if this was the 
primary mechanism through which butyrate alters SC myogenesis.  Treatment with 
butyrate significantly reduced the expression of genes associated with satellite cell 





these transcription factors.  Immunostaining revealed that EZH2 depletion resulted in an 
increase in differentiating SC, but not myotube hypertrophy.  These results indicate that 
while EZH2 ablation may force myogenic differentiation, butyrate may operate through a 
parallel mechanism to enhance the myogenic program.  These findings support the notion 
























Tissue-specific stem cells have the potential to self-renew or differentiate into mature cells, 
contributing to tissue growth and homeostasis.  The muscle specific stem cells, satellite 
cells, maintain the ability to self-renew or differentiate and are required for post-natal 
muscle growth and repair (3, 15, 22).  The use of novel gene sequencing technology in the 
investigation of the genomic regulation of satellite cell fate, has provided insight into how 
the satellite cell epigenome governs myogenesis (31, 42).  Specifically, that changes in the 
chromatin structure and the regulators that direct these changes modulate satellite cell 
activation, proliferation, and differentiation (2, 8, 12, 35).  Interestingly, histone 
deacetylase (HDAC) inhibitors have proven to be effective at enhancing the myogenic 
program of satellite cells (19, 20, 30), but their precise mode of action in remodeling the 
epigenetic landscape of satellite cells remains undetermined.  One such HDAC inhibitor, 
butyrate, is a short-chain fatty acid that has been validated as an effective promoter of 
myogenic differentiation (19), and while the mechanism remains uncertain, indications 
allude to a modification of the epigenetic status (21).  Determining whether these 
presumptive alterations to the satellite cell epigenome triggered by butyrate can be affected 
in vivo would be of great significance in combating muscle disease and improving muscle 
growth. 
 
Satellite cells lie along the muscle fiber beneath basal lamina and plasma membrane (28) 
and remain in a “poised” state, ready to activate, proliferate, and differentiate upon 





well defined through their myogenic lineage (5, 42), marked by their timely expression of 
a hierarchal network of transcription factors (15, 47).  The paired-box 7 (Pax7) 
transcription factor is a hallmark of satellite cell identification and is required for postnatal 
muscle growth and repair (36, 41).  Upon satellite cell activation, Pax7 is upregulated and 
cells will proliferate and begin expressing the basic helix-loop-helix myogenic regulatory 
factor (MRF), MyoD (33).  The transcription factor MyoD is a master regulator of satellite 
cell lineage fate and is responsible for the expression of muscle specific genes through its 
initiation of the differentiation program (45).  Satellite cells that do not express MyoD, or 
have high levels of Pax7 expression compared to MyoD, will self-renew and go back to a 
quiescent state, reserved for the next round of stimulation and activation (34, 49).  MyoD 
has also been found to play a role in repressing the muscle differentiation genes that it is 
associated with until differentiation cues are present (26), and that not all genes that MyoD 
associates with are expressed at the same time (4).  These findings describe the integral 
arrangement and temporal spacing of gene expression during the myogenic program.  
Another MRF, myogenin is also required for proper satellite cell terminal differentiation 
(16) and is regulated by MyoD.  In both a direct and indirect manner, MyoD recruits 
chromatin remodeling enzymes to the myogenin promoter allowing for the binding of 
MyoD to the promoter and allowing for transcription (11, 46).  Myogenin target genes 
include those responsible for appropriate satellite cell fusion and contractile protein 
formation (10, 29).  Myogenin expression marks the transition from myoblast proliferation 
to differentiation (7) and the down-regulation of Pax7, as the two are mutually exclusive 





these transcription factors has been shown to govern the rate in which satellite cells 
progress through their myogenic program (31, 42).  
 
The subset of myogenic progenitor cells the make up the satellite cell pool after 
embryogenesis lie in quiescence and rely on a highly coordinated transcriptional network 
that govern maintenance, activation, and differentiation.  Satellite cell commitment to its 
myogenic lineage is regulated and defined by the epigenome (43), and with new chromatin 
immunoprecipitation sequencing (ChIP-Seq) technology, these epigenetic signatures have 
been defined (24).  Satellite cell quiescence is maintained by the absence of the repressive 
trimethylated lysine 27 residue on the histone H3 protein (H3K27me3) and the presence of 
H3K4me3 (24).  Upon satellite cell activation, most of the H3K4me3 marks remain, but 
repressive H3K27me3 marks are deposited on muscle specific genes (MyoD, MyoG) by 
the Polycomb group (PcG) proteins in association with the transcriptional repressor 
HDAC1 (12).  Satellite cells will then continue to either self-renew, or asymmetrically 
divide and give rise to myogenic daughter cells that begin to express MyoD (22).  These 
committed daughter cells (termed myoblasts) retain the permissive H3K4me3, but lose the 
bivalent H3K27me3 mark, allowing for increased MyoD expression (12).  Prior to 
myoblast differentiation, MyoD associates with HDAC1 resulting in silencing of MyoD-
dependent transcription of muscle specific genes (27, 37).  Myoblasts continue to 
proliferate until pro-differentiation cues lead to a slowing of Pax7 transcription through the 
removal of H3K4me3 and deposition of the repressive H3K27me3 marks by the Polycomb 
repressive complex 2 (PRC2)  (35).  Concomitant removal of the H3K27me3 marks around 





begin (44).  This removal is consistent with a loss of the catalytic subunit, EZH2, of the 
PRC2 protein which regulates the methyltransferase capability of PRC2 and ultimately 
mediates satellite cell differentiation (48).  The HDAC inhibitor butyrate has shown to 
disrupt and downregulate EZH2 expression, resulting in a reduction of H3K27me3 marks 
around lineage specific genes (21). 
 
The use of HDAC inhibitors in satellite cell cultures and animal growth studies have 
yielded positive results with regards to muscle differentiation (19) and growth (13, 17, 25), 
respectively.  Also, EZH2 depleted satellite cells have shown an increased expression of 
myogenin compared in satellite cell cultures (44).  While the benefits of using butyrate on 
in vitro myogenesis are clear, in vivo studies are lacking.  Determining the molecular 
regulators affected by butyrate with regards to muscle growth, may provide targets for 
manipulation in treating myopathies and promoting muscle growth.  In this study, we 
attempt characterize the epigenetic alterations in satellite cells seen by feeding tributyrin, 
a butyrate prodrug.  Also, we attempted to characterize the interaction butyrate has on the 
epigenetic enzyme EZH2 and to determine whether butyrate modulates satellite cell 










Materials and Methods 
 
Animals, diets and experimental protocol 
All animal protocols were approved by the University of Maryland-College Park’s 
Institutional Animal Care and Use Committee.  To assess the impact of dietary tributyrin 
inclusion on in vivo satellite cell epigenetics, 20 cross-bred female piglets (n=10, 24±6h 
old; 1.79±.25kg body weight) were assigned to a treatment diet of either a standard 
commercial milk replacer formula (Advance Liqui-Wean, Milk Specialties Co., Dundee, 
IL) where 175g of powder was reconstituted in water to 1kg total formula (C), or the milk 
replacer formula supplemented with 0.5% (T) total butyric acid in the form of spray dried 
tributyrin (AviPremiumD, Vetagro SpA, Reggio Emilia, Italy).  Tributyrin inclusion was 
on a dry matter basis and coconut oil was used to ensure the diets were isoenergetic.  Piglets 
were housed individually and received formula every 2hrs (0900-2300) at a limit-fed rate 
to match sow reared growth.  One piglet from the T group was removed from the study due 
to non-treatment related health issues.  Body weight and feed intake were recorded daily 
for the duration of the 21d feeding trial.  At sacrifice, Longissumus dorsi (LD) muscle was 
collected and used for all tissue analysis and satellite cell isolation. 
 
Satellite cell isolation and culture 
Satellite cells were isolated according to a procedure modified from Doumit and Merkel 
(14) and Allen et al. (1).  Briefly, LD muscle was excised from neonatal piglets, trimmed 
of connective tissue and minced with scissors.  Tissue fragments were digested with 





for 1h at 37˚C.  Satellite cells were disassociated from tissue fragments by trituration and 
differential centrifugation.  Cells were pre-plated on uncoated 15cm tissue culture dishes 
for 2h (37˚C, 5% CO2) in proliferative growth media (PGM, DMEM + 10% FBS + 
antibiotics- 100U/mL penicillin, 100µg/mL streptomycin, 10µg/mL gentamycin; Thermo 
Fisher Scientific, Waltham, MA) and then seeded on tissue cultured treated dishes coated 
with Poly-L-lysine (100µg/mL ddH2O, Sigma-Aldrich) and fibronectin (10µg/mL PBS, 
Sigma-Aldrich) in PGM until they reached 50% confluence (37˚C, 5%CO2).  Cells were 
then released with 0.05% Trypsin (Thermo Fisher Scientific) and either plated for our 
studies or used for ChIP-Seq analysis. 
 
The effect of tributyrin inclusion on ex vivo satellite cell expression of EZH2 was analyzed 
through their myogenic progression under proliferative and differentiative conditions.  
Satellite cells were seeded at 2,500 cells/cm2 in PGM on to plates coated with Poly-L-
lysine and fibronectin.  After a 24h attachment period, satellite cell proliferated for 48hrs 
and were then induced to differentiate (DM, DMEM + 2% horse serum; Sigma-Aldrich, + 
antibiotics) for an additional 48h with complete media changes daily.  Total RNA was 
isolated (RNeasy; Qiagen, Hilden, Germany) at each 24h time point for gene expression 
analysis. 
 
Satellite cell transfection and butyrate treatment 
Satellite cells were plated and allowed to proliferate in PGM until ~80% of confluence, 
were transfected, treated with 0.5mM sodium butyrate (NaBu), or both (Mixed) for 24h 





targeting the EZH2 transcript (siEZH2) (Dharamcon, Lafayette, CO) or a scrambled 
control (siScrambled) (MISSION Universal Negative Control; Sigma-Aldrich) using 
Lipofectamine 2000 (Thermo Fisher Scientific) for 24h according to the manufacturer’s 
protocol.  Transfection efficiency was ~80% with ~70% knockdown efficiency in EZH2 
transcript.  Total RNA was collected at the time of treatment (D-24) and every 24h for 96h 
(72h after differentiation, D+72).  At the D+72h time point, satellite cells were fixed and 
immunostained for myosin heavy chain expression as an indicator of terminal 
differentiation and myotube formation. 
 
Neonatal piglet muscle tissue analysis 
After the 21d neonatal feeding trial, piglet muscle (LD) was snap frozen in liquid N2 for 
EZH2 gene expression analysis.  Total RNA was isolated by homogenization using tri-
reagent (Thermo Fisher Scientific) with phase separation achieved by chloroform wash.  
RNA was precipitated with 70% ethanol and transferred to RNeasy spin column (Qiagen) 
and purified according to the manufacturers protocol. 
 
Analysis of gene expression 
Total RNA isolated from both neonatal LD muscle and satellite cells were quantified using 
the Quant-iT RiboGreen assay (Thermo Fisher Scientific) according to the manufacturer’s 
protocol.  Harvested RNA was reversed transcribed with the SuperScript IV First-Strand 
Synthesis System (Thermo Fisher Scientific) and treated with the RNase H to ensure 
removal of RNA.  The resulting cDNA was quantified with the Quant-iT OligoGreen assay 





Synergy HTX microplate reader using the Gen 5.0 v3.0 software (BioTek Instruments, 
Winooski, VT).  cDNA was used for qRT-PCR using Bio-Rad’s CFX96 Touch Real-Time 
PCR Detection System and iQ Multiplex Powermix or iQ SYBR Green Supermix.  
Analysis of gene expression and amplification plots were executed with the CFX Manager 
Software (version 3.1, Bio-Rad).  Primers and probes for the multiplexed myogenic genes 
of interest and EZH2 expression (singleplex) were normalized to RPL4 using ∆∆CT method 
(Table 4-1).  For each assay, samples were amplified for 45s at 60˚C for 40 cycles.  Primers 
and probes were designed by Integrated DNA Technologies (Coralville, IA). 
 
Table 4-1.  Primers and probe sequences used for gene expression analysis by quantitative RT-PCR. 
Gene Symbol Gene ID Primer Sequence 5’-3’ Probe and Sequence 5’-3’ 
PAX7α 100625823 F: CAGCAAGCCCAGACAGG R: TCGGATCTCCCAGCTGAA 
(HEX): 
TTGAGGAGTACAAGAGGGAGAACCCA 
MYOD1α 407604 F: CCGACGGCATGATGGATTATAG R: CGACACCGCAGCATTCTT 
(FAM): 
AATAGGTGCCGTCGTAGCAGTTCC 
MYOGα 497618 F: AGTGAATGCAGTTCCCACAG R: AGGTGAGGGAGTGCAGATT 
(Texas Red): 
CAACCCAGGGGATCATCTGCTC 
RPL4α 100038029 F: TGGTGGTTGAAGATAAAGTTGAAAG R: TGAGAGGCATAAACCTTCTTGAT 
(Cy5): 
AACCAAGGAGGCTGTTCTGCTTCT 
EZH2β 100625497 F: GCGGAAGCGTGTAAAATCAGA R: CCTTCGCTGTTTCCACTCTT 
 
---------- 
RPL4β 100038029 F: CAAGAGTAACTACAACCTTC R: GAACTCTACGATGAATCTTC ---------- 
α- Multiplex, probe based qRT-PCR 
β- Singleplex, SYBR Green qRT-PCR 
 
Immunostaining 
Satellite cell cultures were immunostained to determine terminal differentiation and reveal 
myotube formation and satellite cell fusion.  Satellite cells were analyzed for the expression 
of the contractile protein myosin heavy chain (MyHC) after 72h of differentiation.  Satellite 
cells were fixed in 4% paraformaldehyde and permeablized in 0.1% Triton X-100 (Sigma-
Aldrich) in PBS.  Samples were blocked with 10% goat serum in PBST (0.1% Tween-20 





mouse monoclonal anti-MyHC at 10µg/mL (Roche, Indianapolis, IN).  Primary antibodies 
were removed and then incubated with the secondary antibody (AlexaFluor 488 goat anti-
mouse IgG at 1:500 dilution; Jackson Immunoresearch, West Grove, PA) in 5% goat serum 
for 1h at room temperature.  Nuclei were visualized with 4’,6-diamidino-2-phenylindole 
(DAPI) (Sigma-Aldrich).  Images were visualized on a Zeiss AxioObserver Z.1 and 
analyzed with ZenPro automated image analysis suite (Carl Zeiss AG, Oberkochen, 
Germany). 
 
ChIP Library Construction and Sequencing 
ChIP libraries were constructed from primary satellite cells (n=3/treatment group) and 
were utilized to perform ChIP-Seq analysis as previously described (39).  Briefly, 
approximately one million cells/sample were used to obtain formaldehyde-crosslinked 
chromatin that was fragmented into smaller sizes (~150–300 base pairs) by sonication (Cell 
Disrupter 350; Heat Systems Ultrasonics, Plainview, NY) and micrococcal nuclease (New 
England Biolabs, Ipswich, MA) digestion. Chromatin was then immunoprecipitated with 
ChIP-grade H3K27me3 (ab6002) and H3K27ac (ab4729) antibodies (Abcam, Cambridge, 
United Kingdom) and purified to obtain immunoprecipitated DNA.  ChIP DNA was 
repaired by using NEBNext End repair module (New England Biolabs) and 3’A addition 
was performed using NEB Klenow Fragment (New England Biolabs). Then, adaptors 
(Illumina Inc, San Diego, CA) were ligated to the repaired end with T4 DNA ligase (New 
England Biolabs).  After PCR amplification, DNA fragments of 200 – 500bp were selected 
from the agarose gel. The resulting library was sequenced on the Illumina HiSeq 2000 







Raw sequence data quality was checked by FastQC (40). Bowtie, an ultrafast memory-
efficient short read aligner was used to align reads to the pig reference genome Sscrofa10.2 
(Swine Genome Sequencing Consortium) (23). No trimming process was used because of 
high data quality. After quality control and alignment, peak-calling was achieved by using 
Model Based Analysis of ChIP-Seq (MACS) (50). Identification of differentially enriched 
regions between treatment and control groups were accomplished by DiffBind package in 
R (version 3.2.3) (38). Peaks identified with MACS (BAM) were used as input data for 
DiffBind.  EdgeR analysis was run in the DiffBind package and used for Trimmed Mean 
of M-values normalization.  The significance cut-off value for identification of differential 
regions was set to < 0.1 false discovery rate (FDR) for H3K27ac and < 0.05 FDR for 
H3K27me3. Next, the ChIPpeakAnno package in R was used to annotate genomic features 
of those identified differential enrichment regions (51). ChIPpeakAnno allows the extract 
of information overlaps, distances, and relative positions of requested genetic features. 
Gene ontology (GO) enrichment analysis was performed on the online DAVID 
Bioinformatics Resources 6.8 to highlight the most relevant GO terms from the list of 
related gene annotated by ChIPpeakAnno (18). 
  
Gene expression and satellite cell fusion data 
General statistical procedures were analyzed using an F-test in ANOVA (GraphPad Prism 
7, GraphPad Software, Inc., La Jolla, CA).  In the case of a significant F-test, multiple 





to analyze treatment mean differences where indicated.  A probability of P ≤ 0.05 was 
considered significant and a P-value between 0.05 and 0.10 (0.05 < P ≤ 0.10) was 





Tributyrin’s effect on EZH2 gene expression 
Muscle tissue and isolated satellite cells were assessed for tributyrin’s impact on EZH2 
gene expression.  Primary satellite cells were allowed to progress through their myogenic 
lineage ex vivo for 96h.  EZH2 gene expression was analyzed every 24h after plating for 
96h; after 48h of proliferation, and just prior to induction to differentiate, expression was 
reduced in satellite cells from the tributyrin treated piglets as compared to the control 
(P<.10) (Figure 4-1).  EZH2 transcript expression was not significantly reduced 24h after 
plating or 24h after differentiation, and by 48h of differentiation, there were no treatment 
effects on EZH2 gene expression.  Total RNA extracted from whole muscle tissue showed 






















Satellite cells from tributyrin treated piglets (n=3) and control piglets (n=3) were analyzed 
for global levels of genome binding for H3K27me3 and H3K27ac histone marks by ChIP-
Seq.  Tributyrin treatment resulted in 358 of the 532 differentially bound sites being 
significantly reduced for H3K37me3 enrichment based on edgeR (FDR ≤ 0.05).  Analysis 
of H3K27ac revealed 162 differentially enriched regions with an even distribution of 
annotated regions between the treatment groups (FDR ≤ 0.10) (Figure 4-2).  GO 
enrichment analysis from differentially bound sites in satellite cells from tributyrin treated 
animals revealed significant decreases in the enrichment of repressive H3K27me3 marks 
associated with increased myoblast differentiation, negative regulators of cell proliferation, 
and microRNAs involved in satellite cell differentiation as compared to cells from the 






































Figure 4-1. EZH2 expression in primary satellite cells isolated from neonatal piglets fed a control milk 
replacer or a milk replacer supplemented with 0.5% Tributyrin.  Satellite cells were cultured under 
proliferative conditions until ~90% confluence and then induced to differentiate.  Total RNA was 
harvested and relative EZH2 expression was analyzed by qRT-PCR and normalized to RPL4 expression 
(2-∆∆CT).  (Inset) Endogenous fold-change in the expression of EZH2 in satellite cells (control) during the 





control animals.  Conversely, sites involved with positive regulators of cell proliferation 
and increased stem cell maintenance were enriched for H3K27me3 in the tributyrin group 
(Table 4-2).  We performed the same analysis with H3K27ac differentially bound peaks 
found in control and tributyrin clusters; Tributyrin cluster genes were enriched for GO 
terms related to increase cell adhesion, TORC1 complex and microRNAs upregulated 
during myoblast differentiation.  H3K27ac control cluster genes were enriched for GO 



















   



























   






























Table 4-2: Gene Ontology (GO) Analysis of H3K27me3 Differently Bound Peaks  
GO Categories Enriched in H3K27me3 from Satellite Cells Treated with Tributyrin 





MYOD1 myogenic differentiation 1 -2.059 4.2E-04 
SOX11 SRY-box 11 -2.653 3.0E-04 
QKI KH domain containing RNA binding -1.398 4.7E-04 
NTRK3 neurotrophic tyrosine kinase, receptor, type 3 -2.023 1.9E-04 
Negative Regulation of Cell 
Proliferation 
DRD2 dopamine receptor D2 -2.508 3.1E-04 
BTG4 BTG anti-proliferation factor 4 -2.002 1.3E-05 
INSM1 INSM transcriptional repressor 1  -1.486 3.0E-04 
Negative Regulation of Cell 
Response to Growth Factor 
Stimulus 
SLIT2 slit guidance ligand 2  -2.227 4.7E-04 
CASK calcium/calmodulin dependent serine protein kinase -1.308 2.5E-04 
Cell Cycle Arrest 
THBS1 thrombospondin 1 -1.753 4.9E-04 
IL-12B interleukin 12B -2.251 1.8E-07 
Homophilic cell adhesion 
via plasma membrane 
adhesion molecules 
CDH6 cadherin 6 -2.002 1.5E-05 
CDH10 cadherin 10 -1.853 2.5E-04 
FAT3 FAT atypical cadherin 3 -2.201 3.3E-04 
Micro-RNAs 
MIR206 ----- -2.574 4.1E-04 
MIR214 ----- -1.757 4.5E-04 
MIR208B ----- -1.525 5.9E-04 
MIR130A ----- 2.862 2.0E-04 
Positive Regulation of Cell 
Proliferation 
FGF17 fibroblast growth factor 17 2.496 1.2E-08 
RASGRP4 RAS guanylyl releasing protein 4  1.743 2.9E-05 
Germ-line stem cell 









Figure 4-2.  ChIP-Seq of satellite cells selected randomly from control (C, n=3) and tributyrin treated 
(T, n=3) animals for H3K27me3 and H3K27ac histone marks.  (A&B) MA plot of tributyrin-control 
contrast.  Significantly differentially bound sites shown in red.  (C&D) Unsupervised hierarchical 
clustering of differentially bound sites using H3K27me3 (C) and H3K27ac (D) profiles are shown with 






Table 4-3: Gene Ontology (GO) Analysis of H3K27ac Differently Bound Peaks  
GO Categories Enriched in H3K27ac from Satellite Cells Treated with Tributyrin 
GO Term  Associated Gene ID Gene Name/Function Fold Change  P-value 
Regulation of Cell 
Proliferation  DMNT1 DNA (cytosine-5-)-methyltransferase -1.732 1.2E-04 
ATP Binding 
MYO5A myosin VA -3.563 3.8E-05 
PLK2 polo like kinase 2 -2.695 9.1E-07 
EGFR epidermal growth factor receptor -2.643 1.3E-04 
Calcium Ion 
Binding 
SCUBE3 signal peptide, CUB domain, EGF-like 3  -2.407 1.3E-04 
ANXA10 annexin A10 -2.233 4.2E-05 
ITPR3 inositol 1,4,5-triphosphate receptor 3 -2.022 2.7E-05 
Micro-RNAs 
MIR128-1 ----- -2.360 1.4E-04 
MIR181A-1 ----- 1.964 3.8E-06 
MIR210 ----- 2.922 5.7E-07 
Cell Adhesion Via 
Plasma Membrane 
CDH7 cadherin 7 2.819 5.6E-05 
PCDH15 protocadherin 15 3.133 4.6E-07 
TORC1 Complex RPTOR regulatory associated protein of MTOR, complex 1 1.916 9.8E-07 
 
 
Effect of EZH2 knockdown on differentiation 
In order to determine if butyrate works through, or in conjunction with, EZH2 reduction to 
enhance myogenic differentiation, satellite cells isolated from control animals were 
exposed to either butyrate (0.5mM, NaBu), RNAi targeting the EZH2 transcript (siEZH2), 
or both butyrate and siEZH2 (Mixed) during proliferation.  After 24h of exposure to 
butyrate, satellite cell expression of the EZH2 transcript was not significantly reduced as 
compared to the control.  The siEZH2 treatment resulted in a 60% reduction (P<.01) in 
EZH2 transcript expression as compared to siScrambled control.  An additive effect of the 
combination of butyrate and siEZH2 (Mixed) was seen with a 75% reduction (P<.01) in 
EZH2 gene expression compared to the siScrambled treatment (Figure 4-3).  After 24h of 
differentiation (D+24), EZH2 expression was reduced, as compared to levels during 
proliferation, with no significant differences between treatments.  Total RNA was also 





knockdown did not have a significant effect on the expression of the myogenic genes after 
transfection or during differentiation.  Treatment with NaBu alone and NaBu+siEZH2 did 
however, result in reducing Pax7 (P<.01) and MyoD (P<.05) expression ~40% 24h after 
treatment (Figure 4-3), but did not affect myogenin expression (data not shown).  After 
being induced to differentiate, no statistically significant differences in myogenic gene 
expression was found between treatment groups.  After 72h of differentiation, satellite cells 
were fixed and stained for the contractile protein MyHC as an indicator of terminal 
differentiation.  Satellite cells treated with siEZH2 tended (P<.10) to have ~75% increase 
in MyHC+ cells relative to the siScrambled control, but EZH2 knockdown did not result in 



































Figure 4-3. EZH2 knock-down and butyrate 
treatment effect on gene expression in satellite 
cells isolated from untreated neonatal piglets.  
Satellite cells were cultured under proliferative 
conditions until ~80% confluence, treated for 24h, 
and then induced to differentiate.  Satellite cell 
treatment groups: siRNA targeting the EZH2 
transcript (siEZH2), a scrambled control siRNA 
(siScrambled), 0.5mM sodium butyrate (NaBu), or 
both NaBu + siEZH2 (Mixed).  Gene expression 
was analyzed by qRT-PCR and all genes of interest 
were normalized to RPL4.  Relative expression of 
the genes of interest (EZH2, Pax7, and MyoD) 
from the transfected treatments (siEZH2 and 
Mixed) were normalized to siScrambled control 
while the NaBu treatment was normalized to the 














































Figure 4-4. EZH2 knock-down and butyrate 
treatment effect on satellite cell differentiation as 
assessed by myosin heavy chain (MyHC) 
expression 72h after differentiation.  Satellite cells 
were cultured under proliferative conditions until 
~80% confluence, treated for 24h, and then 
induced to differentiate.  Satellite cell treatment 
groups: siRNA targeting the EZH2 transcript 
(siEZH2), a scrambled control siRNA 
(siScrambled), 0.5mM sodium butyrate (NaBu), or 
both NaBu + siEZH2 (Mixed).  (A) Representative 
images of myotube formation revealed by 
immunostaining with anti-MyHC (green); nuclear 
counterstain with DAPI (blue).  (B) The number of 
MyHC+ cells were counted and compared to total 
nuclei.  The number of MyHC+ cells from the 
transfected treatments (siEZH2 and Mixed) were 
normalized to the siScrambled control while the 
NaBu treatment was normalized to the untreated 













The transcriptionally repressive H3K27me3 histone mark deposited by the Polycomb 
EZH2 methyltransferase protein has been implicated in regulating satellite cell 
specification and the differentiation process (2).  It has been demonstrated in other tissue 
specific stem cells that EZH2 expression is regulated by HDACs and can be altered with 
HDAC inhibitors in vitro (7).  Animals treated with butyrate have shown increased 
functionality in models of muscle pathology (14) and increased growth (8); however, the 
molecular mechanisms leading to these outcomes has remained generally unaddressed.  
Our results suggest that dietary inclusion of butyrate is sufficient to alter the expression of 
EZH2 and the epigenetic landscape of satellite cells.  Our data does not indicate that the 
reduction in EZH2 expression caused by butyrate is the sole mechanism through which 
butyrate may alter the myogenic program of satellite cells.  
  
Dietary inclusion of tributyrin resulted in a hastened reduction in EZH2 expression in 
satellite cells ex vivo.  Primary satellite cells from tributyrin treated piglets showed a 
reduction in EZH2 expression just prior to differentiation as compared to the control 
piglets.  After 24h in differentiation media, EZH2 expression was similar between the two 
groups.  These findings indicate that those cells may start the differentiation program 
earlier or may be primed to initiate the differentiation machinery more quickly.  There are 
published data that are consistent with this scenario, showing that an auto-regulatory loop 
exists in which the microRNA miR-214 (discussed below) targets the 3’UTR of EZH2 just 





animals, we performed ChIP-Seq to determine global genome enrichment of the 
H3K27me3 and H3K27ac histone marks. 
 
ChIP-Seq was performed on proliferating primary satellite cells and revealed that treatment 
with tributyrin resulted in a global reduction of H3K27me3 marks, but intriguingly did not 
result in hyperlactation of H3K27.  It would appear that other differentiation cues must be 
necessary in order for histone acetyltransferases (HATs) to be recruited to those locations, 
despite HDAC inhibition.  Our results showed that those regions with differential 
enrichment of H3K27me3 were associated with the GO terms related specifically to 
myoblast differentiation.  Most importantly among these genes was the MRF MyoD which 
had a differentially enriched region 10kb upstream of the transcription start site that was 
reduced for H3K27me3 with tributyrin treatment.  There is evidence that the homeoprotein 
Msx1, Msh homeobox-1, recruits the PRC2 complex to MyoD regulatory regions and 
results in increased repressive H3K27me3 being deposited in several regions (16).  Other 
genes that were associated with regions showing an overall reduction in H3K27me3 were 
related to the GO terms negative regulation of cell proliferation, cell cycle arrest, and 
plasma membrane adhesion molecules.  Conversely, tributyrin treatment resulted in fewer 
H3k27me3 enriched regions as compared to the control; however, those regions that were 
enriched over the control were associated with genes related to the positive regulation of 
cell proliferation.  These results underscore the anti-proliferative and pro-differentiative 
properties attributed to butyrate (12) while also highlighting the epigenetic nature of these 
changes.  Interestingly, our ChIP-Seq results indicate that tributyrin treatment resulted in 





EZH2 expression (6), as detailed above, was enriched for the repressive H3K27me3 in the 
satellite cells of the control animals.  This may explain one way in which EZH2 expression 
was reduced in the satellite cells from the treatment group.  Also, H3K27me3 marks around 
miR-206 were reduced in satellite cells from the tributyrin treatment group.  miR-206 has 
been implicated in repressing Pax7 and allowing for differentiation to take place (3).  
Complementary to this, tributyrin treatment resulted in H3K27ac enrichment near both 
miR-181a and miR-210 which are strongly upregulated during satellite cell differentiation 
(4, 9).  It appears that the beneficial effects of butyrate on satellite cells reported previously 
(5) may be due, at least in part, to a modulation of EZH2 activity. 
 
To investigate whether butyrate’s primary mechanism of action occurs through the down 
regulation of EZH2 expression and subsequent hypomethylation of H3K27, we assessed 
the interaction of EZH2 depletion alone or in concert with butyrate exposure in 
proliferating satellite cells just prior to differentiation.  We found that EZH2 knockdown 
alone had no effect on myogenic gene expression at any time point; however, butyrate 
significantly reduced Pax7 and MyoD gene expression, both required for proper satellite 
cell proliferation and activation (15, 17).  Pax7 is required for satellite cell specification 
(13), but is also crucial for preventing precocious differentiation (10).  It is clear that 
butyrate must act through some other mechanism to silence Pax7 and force myogenic cell 
commitment.  It has been determined that EZH2 is required for Pax7 gene silencing through 
progressive H3K27me3 deposition at the Pax7 promoter (11).  Immunostaining for MyHC+ 
satellite cells revealed that treatment with siEZH2 forced differentiation; however, it did 





form multinucleated myotubes.  These findings are consistent with conditional ablation of 
SUZ12 (another component of PRC2) in myoblasts, with the exception that SUZ12 
ablation resulted in enhanced myotube formation (1).  This may be in part due to the 
inability to assemble H3K27me3 marks about the Pax7 gene.  In the absence of other 
differentiation cues, it was apparent that forcing the differentiation program too early had 
severe repercussions on myotube formation.  The combined action of butyrate and siEZH2 
was not enough to recover appropriate myotube formation.  These results indicate that 
premature EZH2 ablation will inadvertently initiate the differentiation program without the 
appropriate mechanisms in place for satellite cell fusion or myotube hypertrophy. 
 
In our study, we have shown that tributyrin supplementation had a genome-wide impact on 
H3K27me3 mark deposition, primarily due to the interaction of butyrate with the PRC2 
methyltransferase enzyme EZH2.  Our in vitro work demonstrates that a reduction in EZH2 
gene expression is not the only pro-myogenic differentiation cue that may be taking place.  
It has been suggested that an interaction exists where in which HDAC1 complexes with 
EZH2 and they function collectively to trimethylate H3K27 (2).  It is possible that the 
HDAC inhibitory effects may reduce the effect and recruitment of EZH2 to areas 
responsible for muscle gene expression, and that these marks are passed on to subsequent 
daughter cells, as shown in our results (Figure 4-5).  Further investigation is warranted into 
the hyperacetylation of MyoD, as well as the co-immunoprecipitation of the genome that 
is bound by both EZH2 and HDAC1.  Taken together, these observations detail one way 








Figure 4-5.  Regulation of satellite cell activation and differentiation in the presence of butyrate.  In 
undifferentiated, quiescent satellite cells lineage determination genes (i.e. myogenin) are not expressed due 
to the repressive H3K27me3 heterochromatin marks and lack of MyoD locating to the promoter region.  Upon 
activation, MyoD is transcribed and locates to the promoter region of muscle genes (i.e., myogenin).  Under 
normal conditions, MyoD is associated with HDAC1 and H3K27me3 still marks relevant muscle genes 
which prevent precocious differentiation.  Satellite cells that are activated in the presence of butyrate allow 
the early acetylation of MyoD and removal of H3K27me3 marks.  Butyrate inhibits HDAC1 and may 
interfere with PRC2 mediated trimethylation of H3K27.  Inhibition of HDAC1 may also cause early PRC2 
dislocation from muscle gene promoter regions.  During differentiation cues, histone acetyl transferases 
(HATs) are recruited to muscle genes for deposition of the active H3K27ac euchromatin mark.  Histone tail 
acetylation takes place during differentiation, but at a faster pace in the presence of butyrate while repressive 
PRC2 that has already disassociated from muscle gene promoters can now be recruited to the promoters of 







1. Allen RE, Temm-Grove CJ, Sheehan SM, and Rice G. Skeletal muscle satellite 
cell cultures. Methods Cell Biol 52: 155-176, 1997. 
2. Asp P, Blum R, Vethantham V, Parisi F, Micsinai M, Cheng J, Bowman C, 
Kluger Y, and Dynlacht BD. Genome-wide remodeling of the epigenetic landscape 
during myogenic differentiation. Proc Natl Acad Sci U S A 108: E149-158, 2011. 
3. Bentzinger CF, von Maltzahn J, Dumont NA, Stark DA, Wang YX, Nhan K, 
Frenette J, Cornelison D, and Rudnicki MA. Wnt7a stimulates myogenic stem cell 
motility and engraftment resulting in improved muscle strength. The Journal of Cell 
Biology 205: 97-111, 2014. 
4. Bergstrom DA, Penn BH, Strand A, Perry RL, Rudnicki MA, and Tapscott 
SJ. Promoter-specific regulation of MyoD binding and signal transduction cooperate to 
pattern gene expression. Mol Cell 9: 587-600, 2002. 
5. Blais A. Myogenesis in the genomics era. J Mol Biol 427: 2023-2038, 2015. 
6. Blais A, Tsikitis M, Acosta-Alvear D, Sharan R, Kluger Y, and Dynlacht BD. 
An initial blueprint for myogenic differentiation. Genes Dev 19: 553-569, 2005. 
7. Brack AS, Conboy IM, Conboy MJ, Shen J, and Rando TA. A temporal 
switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult 
myogenesis. Cell Stem Cell 2: 50-59, 2008. 
8. Caretti G, Di Padova M, Micales B, Lyons GE, and Sartorelli V. The 
Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle 





9. Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, and Wang DZ. microRNA-1 
and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation 
by repressing Pax7. J Cell Biol 190: 867-879, 2010. 
10. Cicchillitti L, Di Stefano V, Isaia E, Crimaldi L, Fasanaro P, Ambrosino V, 
Antonini A, Capogrossi MC, Gaetano C, Piaggio G, and Martelli F. Hypoxia-
inducible factor 1-alpha induces miR-210 in normoxic differentiating myoblasts. J Biol 
Chem 287: 44761-44771, 2012. 
11. Crist CG, Montarras D, and Buckingham M. Muscle satellite cells are primed 
for myogenesis but maintain quiescence with sequestration of Myf5 mRNA targeted by 
microRNA-31 in mRNP granules. Cell Stem Cell 11: 118-126, 2012. 
12. Davie JK, Cho J-H, Meadows E, Flynn JM, Knapp JR, and Klein WH. 
Target gene selectivity of the myogenic basic helix–loop–helix transcription factor 
myogenin in embryonic muscle. Dev Biol 311: 650-664, 2007. 
13. de la Serna IL, Ohkawa Y, Berkes CA, Bergstrom DA, Dacwag CS, Tapscott 
SJ, and Imbalzano AN. MyoD targets chromatin remodeling complexes to the 
myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol 25: 3997-
4009, 2005. 
14. Dilworth FJ and Blais A. Epigenetic regulation of satellite cell activation during 
muscle regeneration. Stem Cell Res Ther 2: 18, 2011. 
15. Dong L, Zhong X, He J, Zhang L, Bai K, Xu W, Wang T, and Huang X. 
Supplementation of tributyrin improves the growth and intestinal digestive and barrier 





16. Doumit ME and Merkel RA. Conditions for isolation and culture of porcine 
myogenic satellite cells. Tissue and Cell 24: 253-262, 1992. 
17. Dumont NA, Bentzinger CF, Sincennes MC, and Rudnicki MA. Satellite Cells 
and Skeletal Muscle Regeneration. Compr Physiol 5: 1027-1059, 2015. 
18. Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN, and 
Klein WH. Muscle deficiency and neonatal death in mice with a targeted mutation in the 
myogenin gene. Nature 364: 501-506, 1993. 
19. Huang C, Song P, Fan P, Hou C, Thacker P, and Ma X. Dietary Sodium 
Butyrate Decreases Postweaning Diarrhea by Modulating Intestinal Permeability and 
Changing the Bacterial Communities in Weaned Piglets. J Nutr 145: 2774-2780, 2015. 
20. Huang da W, Sherman BT, and Lempicki RA. Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 
2009. 
21. Iezzi S, Cossu G, Nervi C, Sartorelli V, and Puri PL. Stage-specific 
modulation of skeletal myogenesis by inhibitors of nuclear deacetylases. Proc Natl Acad 
Sci U S A 99: 7757-7762, 2002. 
22. Iezzi S, Di Padova M, Serra C, Caretti G, Simone C, Maklan E, Minetti G, 
Zhao P, Hoffman EP, Puri PL, and Sartorelli V. Deacetylase Inhibitors Increase 
Muscle Cell Size by Promoting Myoblast Recruitment and Fusion through Induction of 
Follistatin. Dev Cell 6: 673-684, 2004. 
23. Juan AH, Kumar RM, Marx JG, Young RA, and Sartorelli V. Mir-214-
dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic 





24. Jung JW, Lee S, Seo MS, Park SB, Kurtz A, Kang SK, and Kang KS. Histone 
deacetylase controls adult stem cell aging by balancing the expression of polycomb genes 
and jumonji domain containing 3. Cell Mol Life Sci 67: 1165-1176, 2010. 
25. Kuang S, Kuroda K, Le Grand F, and Rudnicki MA. Asymmetric Self-
Renewal and Commitment of Satellite Stem Cells in Muscle. Cell 129: 999-1010, 2007. 
26. Langmead B, Trapnell C, Pop M, and Salzberg SL. Ultrafast and memory-
efficient alignment of short DNA sequences to the human genome. Genome Biol 10: R25, 
2009. 
27. Le Gall M, Gallois M, Seve B, Louveau I, Holst JJ, Oswald IP, Lalles JP, and 
Guilloteau P. Comparative effect of orally administered sodium butyrate before or after 
weaning on growth and several indices of gastrointestinal biology of piglets. Br J Nutr 
102: 1285-1296, 2009. 
28. Liu L, Cheung TH, Charville GW, Hurgo BM, Leavitt T, Shih J, Brunet A, 
and Rando TA. Chromatin modifications as determinants of muscle stem cell quiescence 
and chronological aging. Cell Rep 4: 189-204, 2013. 
29. Lu H, Su S, and Ajuwon KM. Butyrate supplementation to gestating sows and 
piglets induces muscle and adipose tissue oxidative genes and improves growth 
performance. J Anim Sci 90 Suppl 4: 430-432, 2012. 
30. Mal A and Harter ML. MyoD is functionally linked to the silencing of a 
muscle-specific regulatory gene prior to skeletal myogenesis. Proc Natl Acad Sci U S A 





31. Mal A, Sturniolo M, Schiltz RL, Ghosh MK, and Harter ML. A role for 
histone deacetylase HDAC1 in modulating the transcriptional activity of MyoD: 
inhibition of the myogenic program. EMBO J 20: 1739-1753, 2001. 
32. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 9: 
493-495, 1961. 
33. Millay DP, O'Rourke JR, Sutherland LB, Bezprozvannaya S, Shelton JM, 
Bassel-Duby R, and Olson EN. Myomaker is a membrane activator of myoblast fusion 
and muscle formation. Nature 499: 301-305, 2013. 
34. Minetti GC, Colussi C, Adami R, Serra C, Mozzetta C, Parente V, Fortuni S, 
Straino S, Sampaolesi M, Di Padova M, Illi B, Gallinari P, Steinkuhler C, 
Capogrossi MC, Sartorelli V, Bottinelli R, Gaetano C, and Puri PL. Functional and 
morphological recovery of dystrophic muscles in mice treated with deacetylase 
inhibitors. Nat Med 12: 1147-1150, 2006. 
35. Moresi V, Marroncelli N, and Adamo S. New insights into the epigenetic 
control of satellite cells. World J Stem Cells 7: 945-955, 2015. 
36. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, 
Souidi M, Cuvellier S, and Harel-Bellan A. The microRNA miR-181 targets the 
homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol 8: 
278-284, 2006. 
37. Olguin HC and Olwin BB. Pax-7 up-regulation inhibits myogenesis and cell 






38. Olguin HC and Pisconti A. Marking the tempo for myogenesis: Pax7 and the 
regulation of muscle stem cell fate decisions. J Cell Mol Med 16: 1013-1025, 2012. 
39. Olguin HC, Yang Z, Tapscott SJ, and Olwin BB. Reciprocal inhibition 
between Pax7 and muscle regulatory factors modulates myogenic cell fate determination. 
J Cell Biol 177: 769-779, 2007. 
40. Palacios D, Mozzetta C, Consalvi S, Caretti G, Saccone V, Proserpio V, 
Marquez VE, Valente S, Mai A, Forcales SV, Sartorelli V, and Puri PL. 
TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links inflammation to 
the epigenetic control of muscle regeneration. Cell Stem Cell 7: 455-469, 2010. 
41. Parker MH, Seale P, and Rudnicki MA. Looking back to the embryo: defining 
transcriptional networks in adult myogenesis. Nat Rev Genet 4: 497-507, 2003. 
42. Prasad KN. Butyric acid: a small fatty acid with diverse biological functions. Life 
Sci 27: 1351-1358, 1980. 
43. Puri PL, Iezzi S, Stiegler P, Chen TT, Schiltz RL, Muscat GE, Giordano A, 
Kedes L, Wang JY, and Sartorelli V. Class I histone deacetylases sequentially interact 
with MyoD and pRb during skeletal myogenesis. Mol Cell 8: 885-897, 2001. 
44. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning 
MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, 
and Carroll JS. Differential oestrogen receptor binding is associated with clinical 
outcome in breast cancer. Nature 481: 389-393, 2012. 
45. Schmidt D. ChIP-seq: using high-throughput sequencing to discover protein-





46. Schmieder R and Edwards R. Quality control and preprocessing of 
metagenomic datasets. Bioinformatics 27: 863-864, 2011. 
47. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, and 
Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell 
102: 777-786, 2000. 
48. Sincennes MC, Brun CE, and Rudnicki MA. Concise Review: Epigenetic 
Regulation of Myogenesis in Health and Disease. Stem Cells Transl Med 5: 282-290, 
2016. 
49. Spivakov M and Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev 
Genet 8: 263-271, 2007. 
50. Stojic L, Jasencakova Z, Prezioso C, Stützer A, Bodega B, Pasini D, 
Klingberg R, Mozzetta C, Margueron R, Puri PL, Schwarzer D, Helin K, Fischle W, 
and Orlando V. Chromatin regulated interchange between polycomb repressive complex 
2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal 
muscle cells. Epigenetics Chromatin 4: 16, 2011. 
51. Tapscott SJ. The circuitry of a master switch: Myod and the regulation of 
skeletal muscle gene transcription. Development 132: 2685-2695, 2005. 
52. Venuti JM, Morris JH, Vivian JL, Olson EN, and Klein WH. Myogenin is 
required for late but not early aspects of myogenesis during mouse development. J Cell 
Biol 128: 563-576, 1995. 
53. von Maltzahn J, Jones AE, Parks RJ, and Rudnicki MA. Pax7 is critical for 
the normal function of satellite cells in adult skeletal muscle. Proceedings of the National 





54. Wang J. The Msx1 Homeoprotein Recruits Polycomb to the Nuclear Periphery 
during Development. 21: 575-588, 2011. 
55. Wang YX, Dumont NA, and Rudnicki MA. Muscle stem cells at a glance. J 
Cell Sci 127: 4543-4548, 2014. 
56. Woodhouse S, Pugazhendhi D, Brien P, and Pell JM. Ezh2 maintains a key 
phase of muscle satellite cell expansion but does not regulate terminal differentiation. J 
Cell Sci 126: 565-579, 2013. 
57. Yoshida N, Yoshida S, Koishi K, Masuda K, and Nabeshima Y. Cell 
heterogeneity upon myogenic differentiation: down-regulation of MyoD and Myf-5 
generates 'reserve cells'. J Cell Sci 111 ( Pt 6): 769-779, 1998. 
58. Zhang K, Sha J, and Harter ML. Activation of Cdc6 by MyoD is associated 
with the expansion of quiescent myogenic satellite cells. J Cell Biol 188: 39-48, 2010. 
59. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, 
Nusbaum C, Myers RM, Brown M, Li W, and Liu XS. Model-based analysis of ChIP-
Seq (MACS). Genome Biol 9: R137, 2008. 
60. Zhu LJ, Gazin C, Lawson ND, Pages H, Lin SM, Lapointe DS, and Green 
MR. ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. 





Chapter 5:  General Conclusions 
 
 
The objective of these studies was to determine what impact butyrate has on satellite 
cell myogenesis and its efficacy as a muscle a growth promoter in the form of tributyrin.  
Positive results from previous cell culture experiments with butyrate and other histone 
deacetylase (HDAC) inhibitors, our own satellite cell culture study, and animal growth 
studies warranted further exploration as to the effect of butyrate on muscle growth and 
satellite cell behavior.  Our results from the first of two successive animal trials 
indicated that butyrate may alter the ability of satellite cells to differentiate into 
myofibers, whereby increasing myonuclear content.  The second animal trial supported 
our hypothesis, that tributyrin promoted muscle growth.  Further analysis revealed 
satellite cells from tributyrin treated animals had a greater myogenic capacity and were 
“poised” for enhanced differentiation.  A reduction in repressive H3K27me3 histone 
mark around key differentiation genes confirmed previous reports that butyrate 
interferes with the methyltransferase ability of the polycomb repressive complex-2 
(PRC2).  However, through our knock-down experiment, we determined that this may 
not be the sole mechanism through which butyrate alters the ability of satellite cells to 
progress through their myogenic lineage.  Taken together, these results highlight the 
potential impact that butyrate and tributyrin has on the promotion of muscle growth 
through altered satellite cell programming. 
 
Previous in vitro application of sodium butyrate on satellite cell myogenesis has had 





to physiologically relevant concentrations (0-1.0mM) of sodium butyrate.  When 
examining satellite cell proliferation, cells demonstrated the typical response of cell 
cycle arrest to butyrate treatment.  Most importantly, we found an increase in terminal 
differentiation ability of satellite cells treated with butyrate, marked by the upregulation 
of the terminal differentiation gene, myogenin.  These results warranted further analysis 
to determine if this effect could be obtained from in vivo supplementation of butyrate.    
 
The results of the first animal trial revealed that neonatal piglets treated with tributyrin, 
a less caustic way to sustain circulating butyrate concentrations, for 21-days had 
significant increase in DNA content in muscle tissue.  An increased DNA:protein ratio 
suggested that an increase in myonuclear content had resulted from tributyrin 
treatment.  This warranted a second animal trial of sustained duration to last through 
weaning.  Animals that had received tributyrin in their milk replacer ended the study 
weighing significantly more than animals that received just the standard milk replacer.  
We attribute this increase in weight to enhanced muscle growth, supported significant 
increases in the loin area and fiber cross-sectional area from the tributyrin treated pigs.  
We did not find any discernable differences in feed efficiency, nor tributyrin’s effect 
on muscle growth when supplemented post-weaning.  Satellite cells from the first 
animal study we then analyzed for any programming effect that tributyrin 
supplementation may have caused.  Similar to our in vitro study, satellite cells from 
treated animals showed enhanced terminal differentiation and increased myogenin 
expression, supporting the assertion that tributyrin supplementation has a lasting 





Given that the most dramatic differences on muscle growth was seen between the 
neonatal tributyrin treatment groups, we analyzed satellite cells from tributyrin treated 
animals to ascertain changes in the epigenetic landscape.  We found that tributyrin 
treatment reduced the expression of the enzymatic subunit of PRC2 (enhancer of zeste 
homolog-2, EZH2) just prior to differentiation.  EZH2 is responsible for the 
trimethylation of H3K27 around key muscle specific genes.  To further investigate 
whether this had an effect on deposition of the repressive H3K27me3 mark, and if the 
HDAC inhibitory properties of tributyrin affected acetylation at H2K27 (H3K27ac), 
we performed ChIP-Seq analysis.  We found a global reduction of H3K27me3 marks 
in those cell from tributyrin treated animals with specific reductions around those genes 
with associated the gene ontology (GO) terms myoblast differentiation, negative 
regulation of cell proliferation, and miRNAs upregulated during differentiation.  There 
did not seem to be any differences in the number of H3K27ac histone mark enrichment 
sites due to tributyrin treatment; however, regions associated with the GO terms 
calcium ion binding and ATP binding were reduced by tributyrin treatment as 
compared to the control.  This prompted us to determine what interaction existed 
between butyrate and PRC2.  To this end we treated satellite cells with butyrate, a short-
interfering RNA (siRNA) targeting the EZH2, or both butyrate and the siRNA.  While 
butyrate may be interfering with EZH2 expression, we assert that another mechanism 
must act in concert with this interference.  Butyrate treatment resulted in significant 
reduction of Pax7 expression while EZH2 depleted satellite cells showed no changes 





butyrate can alter the epigenetic landscape through EZH2 modulation, but that HDAC 
inhibition is also key for enhanced terminal differentiation. 
 
In closing, we have shown that dietary inclusion of butyrate in the form of tributyrin 
has the potential to serve as a possible promoter of muscle growth and that the 
myogenic programming of those satellite cells from treated animals may be altered.  
The benefit of dietary tributyrin inclusion is most apparent during the earliest stages of 
life, when satellite cells are in a constant state of activation and proliferation.  Given 
the similarities between fetal myogenesis and post-natal myogenesis governed by 
satellite cell activation, proliferation, and differentiation, it would seem that tributyrin 
supplementation during gestation may be warranted.  Satellite cells also go through 
periods of intense activation during bouts of injury, tributyrin or butyrate treatment may 
be offered as a therapeutic to enhance healing and functional outcomes during such 
afflictions.         
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